fbpx
900 922 300

Publicaciones ciéntificas

Publicaciones Científicas

  • Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals. Corzo L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R and Cacabelos R. 2020. Nutrients.
  • DNA Methylation in Neurodegenerative and Cerebrovascular Disorders. Martínez-Iglesias O, Carrera I, Carril JC, Fernández-Novoa L, Cacabelos N and Cacabelos R. 2020. Int. J. Mol. Sci
  • Sirtuins in Alzheimer’s disease: SIRT2-Related GenoPhenotypes and implications for PharmacoEpiGenetics. Authors: Ramón Cacabelos *, Alex G. Kazantsev , Alex V. Vostrov , Lola Corzo, Pablo Cacabelos , Dmitry Goldgaber , Natalia Cacabelos , Juan Carlos Carril
  • Pharmacogenetics of Atremorine‐induced neuroprotection and dopamine response in Parkinson Disease. Cacabelos R, Carrera I, Alejo R, Fernández-Novoa L, Cacabelos P, Corzo L, Rodríguez S, Alcaraz M, Tellado I, Cacabelos N, Pego R, Carril JC. 2019. Planta Med.
  • Carrera I, Martínez O, Cacabelos R. Neuroprotection with Natural Antioxidants and Nutraceuticals in the Context of Brain Cell Degeneration: The Epigenetic Connection. Curr Top Med Chem. 2019;19(32):2999-3011. DOI: 10.2174/1568026619666191202155738.
  • Cacabelos R, Meyyazhagan A, Carril JC, Cacabelos R, Teijido O. Pharmacogenetics of vascular risk factors in Alzheimer’s Disease. J Pers Med 2018; 8(3). Doi:10.3390/jpm8010003.
  • In vitro and in vivo cytotoxic effect of AntiGan against tumor cells. Lombardi VRM, Carrera I, Cacabelos R. 2018. Experimental and Therapeutic Medicine.
  • Basic and Clinical Studies with Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders. Cacabelos R, Lombardi VRM, Fernández-Novoa L, Carrera I, Cacabelos P, Corzo L, Carril JC, Teijido O. 2018. Chapter 6. Studies in Natural Products Chemistry, Volume 59.
  • The search for biomarine derived compounds with immunomodulatory activity. Lombardi VRM, Corzo L, Carrera I and Cacabelos R. 2018. Journal of Exploratory Research in Pharmacology.
  • Cacabelos R. The Incorporation of Pharmaco Genomics to Drug Development in Neuropsychiatric Disorders. Nov Appro Drug Des Dev 1(4): NAPDD.MS.ID.555569 (2017)
  • Cacabelos R. 2017. Parkinson’s Disease: From Pathogenesis to Pharmacogenomics. Int J Mol Sci 18, 551: 1-28.
  • Carrera I, Fernandez-Novoa L, Sampedro C, Cacabelos R.2017. Neuroprotective effect of Atremorine in an experimental model of Parkinson´s disease. Curr Pharm Des. doi: 10.2174/1381612823666170210143530. [Epub ahead of print] PubMed PMID: 28190394.
  • Carril JC, Cacabelos R. 2017. Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration. Curr Gen 18 (4): [E-pub Abstract Ahead of Print]
  • Corzo L, Rodriguez S, Alejo R, Fernandez-Novoa L, Aliev G, Cacabelos R. 2017. E-MHK-0103 (MineraxinTM): A Novel Nutraceutical with Biological Properties in Menopausal Conditions. Curr Drug Metab 18(1): 39-49.
  • Del Coso J, Valero M, Salinero JJ, Lara B, Díaz G, Gallo-Salazar C, Ruiz-Vicente D, Areces F, Puente C, Carril JC, Cacabelos R. 2017. ACTN3 genotype influences exercise-induced muscle damage during a marathon competition. Eur J Appl Physiol, 117(3):409-416. doi: 10.1007/s00421-017-3542-z.
  • Fernández-Novoa L, Corzo S, Seoane, Cacabelos R. 2017. A Genomic Approach to Histamine Function. J Gen Med Pharm 2(1): 233-240.
  • Lombardi VRM, Carrera I, Cacabelos R. 2017. In Vitro Screening for Cytotoxic Activity of Herbal Extracts. Evidence-Based Complementary and Alternative Medicine 2017: 1-8. Article ID 2675631. doi:10.1155/2017/2675631
  • Romero A, Parada E, González-Lafuente L, Farré-Alins V, Ramos E, Cacabelos R, Egea J. 2017. Neuroprotective effects of E-PodoFavalin-15999 (Atremorine®). CNS Neurosci Ther 23(5): 450-452.
  • Teijido O, Carril JC, Cacabelos R. 2017. Population-based study of risk polymorphisms associated with vascular disorders and dementia. Curr Gen 18 (6): [E-pub Abstract Ahead of Print]
  • Torrellas C, Carril JC, Cacabelos R. 2017. Optimization of antidepressant use with pharmacogenetic strategies. Curr Genom 18 (4) [E-pub Abstract Ahead of Print]
  • Cacabelos R. Proteomic biomarkers in Alzheimer’s disease. Diagn Pathol Open 2016; 1:1. http://dx.doi.org/10.4172/DPO.1000103.
  • Cacabelos R. Nutriepigenomics: Mending ideas in nutrition, health and disease. J Nutr Sci 2016; 6:1. http://doi.org/10.4172/2155-9600.100e124.
  • Cacabelos R1,2, Teijido O1,3, Carril JC1,4. Can cloud-based tools accelerate Alzheimer’s disease drug discovery? Expert Opin Drug Discov. 2016 Mar;11(3):215-23. doi: 10.1517/17460441.2016.1141892. Epub 2016 Feb 3.
  • Cacabelos R, Reddy VP, Aliev G1. Editorial: Neurodegeneration, Oxidative Stress, Metabolic Syndrome, Drug Design and Development: Clinical Implications. CNS Neurol Disord Drug Targets. 2016;15(2):126.
  • Cacabelos R1, Torrellas C, Carrera I, Cacabelos P, Corzo L, Fernández-Novoa L, Tellado I, Carril JC, Aliev G. Novel Therapeutic Strategies for Dementia. CNS Neurol Disord Drug Targets. 2016;15(2):141-241.
  • Cacabelos R. ADHD: Challenges for a better future. Gen-T International 2016; 4:3-5.
  • Cacabelos R, Torrellas C, Tellado I, Cacabelos P. Genomics, pathogenesis, treatment and Pharmacogenomics of attention-deficit/hyperactivity disorder. Gen-T International 2016; 4:8-134.
  • Cacabelos R, Torrellas C, Fernández-Novoa L, Aliev G. Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection. Curr Pharm Des. 2016;22(7):819-48.
  • Carrera I1, Fernandez-Novoa L, Aliev G, Vigo C, Cacabelos R. Validating Immunotherapy in Alzheimer’s Disease: The EB101 Vaccine. Curr Pharm Des. 2016;22(7):849-58.
  • Cacabelos R. Trial-and-Error versus Personalized Treatment in Depression: The Power of Pharmacogenomics. J Psychiatry Depress Anxiety 2016; 2:004.
  • Cacabelos R. Histamine: The Missing Link in the Pathogenesis of Some Brain Disorders. Journal of Clinical and Experimental Neuroimmunology 2016; 1:1. http://dx.doi.org/10.4172/jceni.1000103.
  • Cacabelos R. Epigenetics of Brain Disorders: The Paradigm of Alzheimer’s disease. J Alzheimers Dis Parkinsonism 2016; 6:229. Doi: 10.4172/2161-0460.1000220.
  • Cacabelos R. The complexity of Alzheimer’s disease pharmacogenomics and metabolomics in drug development. Metabolomics 2016; 2:6. http://dx-doi.org/10.4172/2153-0769.1000e145.
  • Aliev G, Cacabelos R, Prakash Reddy V. Editorial: Metabolic Disorders, Drug Development, Drug Design and Biomarkers. Curr Pharm Des. 2016; 22:765-767.
  • Cacabelos R. Proteomic biomarkers in Alzheimer’s disease. Diagn Pathol Open 2016; 1:1. http://dx.doi.org/10.4172/DPO.1000103.
  • Cacabelos R. Nutriepigenomics: Mending ideas in nutrition, health and disease. J Nutr Sci 2016; 6:1. http://doi.org/10.4172/2155-9600.100e124.
  • Cacabelos R, Teijido O, Carril JC. Can cloud-based tools accelerate Alzheimer’s disease drug discovery? Expert Opin Drug Discov. 2016 Mar;11(3):215-23. doi: 10.1517/17460441.2016.1141892. Epub 2016 Feb 3.
  • Cacabelos R, Reddy VP, Aliev G. Editorial: Neurodegeneration, Oxidative Stress, Metabolic Syndrome, Drug Design and Development: Clinical Implications. CNS Neurol Disord Drug Targets. 2016;15(2):126.
  • Cacabelos R, Torrellas C, Carrera I, Cacabelos P, Corzo L, Fernández-Novoa L, Tellado I, Carril JC, Aliev G. Novel Therapeutic Strategies for Dementia. CNS Neurol Disord Drug Targets. 2016;15(2):141-241.
  • Patiño P, Parada E, Farré-Alins V, Molz S, Cacabelos R, Marco-Contelles J, López MG, Tasca CI, Ramos E, Romero A, Egea J. Melatonin protects against oxygen and glucose deprivation by decreasing extracelular glutamate and Nox-derived ROS in rat hippocampal slices. NeuroToxicology 2016; 57:61-68.
  • Cacabelos R. ADHD: Challenges for a better future. Gen-T International 2016; 4:3-5.
  • Cacabelos R, Torrellas C, Tellado I, Cacabelos P. Genomics, pathogenesis, treatment and Pharmacogenomics of attention-deficit/hyperactivity disorder. Gen-T International 2016; 4:8-134.
  • Cacabelos R, Torrellas C, Fernández-Novoa L, Aliev G. Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection. Curr Pharm Des. 2016;22(7):819-48.
  • Carrera I, Fernandez-Novoa L, Aliev G, Vigo C, Cacabelos R. Validating Immunotherapy in Alzheimer’s Disease: The EB101 Vaccine. Curr Pharm Des. 2016;22(7):849-58.
  • Cacabelos R. Trial-and-Error versus Personalized Treatment in Depression: The Power of Pharmacogenomics. J Psychiatry Depress Anxiety 2016; 2:004.
  • Cacabelos R. Histamine: The Missing Link in the Pathogenesis of Some Brain Disorders. Journal of Clinical and Experimental Neuroimmunology 2016; 1:1. http://dx.doi.org/10.4172/jceni.1000103.
  • Cacabelos R. Epigenetics of Brain Disorders: The Paradigm of Alzheimer’s disease. J Alzheimers Dis Parkinsonism 2016; 6:229. Doi: 10.4172/2161-0460.1000220.
  • Cacabelos R. The complexity of Alzheimer’s disease pharmacogenomics and metabolomics in drug development.Metabolomics 2016; 2:6. http://dx-doi.org/10.4172/2153-0769.1000e145.
  • Cacabelos R, Torrellas C, Teijido O, Carril JC. Pharmacogenetic considerations in the treatment of Alzheimer’s disease. Pharmacogenomics. 2016 Jun;17(9):1041-74. doi: 10.2217/pgs-2016-0031. Epub 2016 Jun 13.
  • Cacabelos R, Torrellas C, Fernández-Novoa L, López-Muñoz F. Histamine and Immune Biomarkers in CNS Disorders. Mediators Inflamm. 2016;2016:1924603. doi: 10.1155/2016/1924603. Epub 2016 Apr 13.
  • Cacabelos R. Biochemical changes and cardiovascular function in Parkinson’s disease: Precautionary notes. Clin Med Biochemistry Open Access 2016; 2:2. DOI: 10.4172/2471-2663.1000E102.
  • Cacabelos R. Genomic Medicine: A conceptual revolution in medical practice. J Genomic Med Pharmacogenomics 2016; 1:1-2.
  • Cacabelos R, Fernández-Novoa L, Alejo R, Corzo L, Alcaraz M, Nebril L, Cacabelos P, Fraile C, Carrera I, Carril JC. E-PodoFavalin-15999 (Atremorine®)-induced dopamine response in Parkinson’s Disease: Pharmacogenetics-related effects. J Genomic Med Pharmacogenomics 2016; 1:1-26.
  • Carril JC, Cacabelos R. Genomics and Pharmacogenomics of cerebrovascular disorders. J Genomic Med Pharmacogenomics 2016; 1:27-75.
  • Arun M, Gomathi M,Mahalaxmi I, Kumat AK, Balamuralikrishnan B, Kumar R, Kumar M, Easwaran M, Raman N, Gowtham M, Sureshkumar S, Haripriya KB, Elipilla P, Balchandar V, Sasikala K,
  • Cacabelos R. Cytogenetics and selected biochemical phenotypes in Indian schizophrenic patients. J Genomic Med Pharmacogenomics 2016; 1:81-94.
  • Teijido O, Cacabelos R. Interrogating the epigenome to unveil the secrets of neurodegeneration: Promising epigenetic therapies. J Genomic Med Pharmacogenomics 2016; 1:95-150.
  • Cacabelos R. Parkinson’s disease: Old concepts and new challenges. Scientific Pages Alzheimers Dis Dement 2016; 1:001.
  • Cacabelos R. Novel biotechnological products from natural sources: Nutri/Pharmacogenomic component. J Nutr Food Sci 2016; 6:6. DOI: 10.4172/2155-9600.1000e133.
  • Cacabelos R, Fernández-Novoa L, Alejo R, Corzo L, Rodríguez S, Alcaraz M, Nebril L, Cacabelos P, Fraile C, Carrera I, Carril JC. E-PodoFavalin-15999 (Atremorine®)-induced neurotransmiiter and hormonal response in Parkinson’s Disease. J Exlor Res Pharmacol 2016; 1:1-12. DOI: 10.14218/JERP.2016.00031.
  • Cacabelos R, Carril JC, Cacabelos P, Teijido O, Goldgaber D. Pharmacogenomics of Alzheimer’s Disease: Genetic Determinants of Phenotypic Variation and Therapeutic Outcome. J Genomic Med Pharmacogenomics 2016; 1(2): 151-209.
  • Tellado I, Torrellas C, Carril JC, Fraile C, Cacabelos R. Age and Genotype-Related Changes in Brain Bioactivity Networks: Potential Influence on Drug Monitoring and Neurodegeneration J Genomic Med Pharmacogenomics 2016; 1(2): 210-224.
  • Carrera I, Fernandez-Novoa L, Vigo C, Cacabelos R. Sphingosine-1-phosphate (S1P)-Containing Niosomes as Vehicle to Deliver Amyloid-β in a Novel Alzheimer´s Disease Vaccine J Genomic Med Pharmacogenomics 2016; 1(2): 225-232.
  • Carrera I, Etcheverría I, Fernández-Novoa L, Lombardi VRM, Lakshmana MK, Cacabelos R, Vigo C. A comparative evaluation of a novel vaccine in APP/PS1 mouse models of Alzheimer’s Disease. BioMed Research International 2015; ID 807146. Dx.doi.org/10.1155/2015/807146.
  • Chioua M, Pérez M, Bautista-Aguilera OM, Yáñez M, López MG, Romero A, Cacabelos R, Puig de la Bellacasa R, Brogi S, Butini S, Borrell JI, Marco-Contelles J. Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer’s disease. Mini-Reviews in Medicinal Chemistry 2015; 15:648-658.
  • Cacabelos R, Torrellas C, Carrera I. Opportunities in Pharmacogenomics for the treatment of Alzheimer’s Disease. Future Neurology 2015; 10(3):229-252.
  • Cacabelos R. New insights into the pathogenesis and pharmacogenomics of attention deficit hyperactivity disorder. Metabolomics 2015, 5:146. Doi:10.4172/2153-0769.1000146.
  • Cacabelos R.Pharmacoepigenomics and the metabolomics of drug efficacy and safety. Metabolomics 5:e140. Doi:10.4172/2153-0760.10000e140.
  • Cacabelos R, Goldgaber D, Roses AD, Vostrov A, Matsuki H, Torrellas C, Cacabelos P, Corzo D, Carril JC, Fernández-Novoa L, Carrera I. Gene interactions in the Pharmacogenomics of Alzheimer’s Disease. Sciforschen Genetics and Gene Therapy 2015; 1(1): http://dx.doi.org/10.16966/sggt.102.
  • Perianes-Cachero A, Canellas S, Aguado-Llera D, Frago LM, Toledo-Lobo MV, Carrera I, Cacabelos R, Chowen JA,Argente J, Arilla-Ferreiro E, Barrios V. Reduction in Aβ-induced cell death in the hippocampus of 17β-estradiol-treated female rats is associated with an increase in IGF-1 signaling and somatostatinergic tone. J Neurochem 2015 (Oct 7) doi:10.1111/jnc.13381.
  • Cacabelos R, Torrellas C. Pharmacogenomics of antidepressants. HSOA Journal ofPsychiatry, Depression& Anxiety 2015; 1:001.
  • Cacabelos R. Impact of genomic medicine on the future of Neuropsychopharmacology. J Neuropsychopharmacol Mental Health 2015, 1:1. Http://dx.doi.org/10.4172/jnpmh.1000e101.
  • Cacabelos R. Epigenetic biomarkers in cancer. Clin Med Biochemistry 2015, 1:1. http://dx-doi.org/10.4172/cmbm.1000e101.
  • Cacabelos R. Metabolomics of drug resistance in cancer: The Epigenetic Component. Metabolomics 2015;5:4. http://dx-doi-org/10.4172-0769.1000e141.
  • Cacabelos R, Torrellas C. Epigenetics of aging and Alzheimer’s disease: Implications for pharmacogenomics and drug response. International Journal of Molecular Sciences 2015; 16:30483-30543; doi:10.3390/ijms161226236.
  • Cacabelos R. Proteoepigenomic biomarkers of brain disorders. Metabolomics 2015; 5: e143. doi:10.4172/2153-0769.1000e143.
  • Torrellas C, Risso A, Carril JC, Cacabelos R. Optimización del uso deantidepresivos con estrategias farmacogenéticas. Gen-T 2015; 10:17-26.
  • Ramos E, Marco Contelles J, Cacabelos R, Romero A. Potencial terapéutico de la melatonina en combinación con otros fármacos frente a la neurodegeneración. Gen-T 2015; 10:43-52.
  • Del Coso J, Lara B, Salinero JJ, Areces F, Gallo-Salazar C, Ruiz-Vicente D, Cacabelos R. La importancia del sodio para el rendimiento y la salud del deportista. La fisiología del ejercicio y la genética como elementos clave para el diseño de las futuras bebidas deportivas y los suplementos nutricionales. Gen-T 2015; 10:63-71.
  • Carril JC, Cacabelos R. La Tarjeta Farmacogenética Inteligente. Desarrollo de la nueva Tarjeta Farmacogenética EuroEspes para el tratamiento farmacológico personalizado. Gen-T 2015; 10:72-114.
  • Tellado I, Carril JC, Couceiro V, Fraile C, Torrellas C, Cacabelos R. Impacto del genotipo AGT sobre la actividad cerebral en la demencia vascular. Gen-T 2015; 10:137-142.
  • Aliev G1, Cacabelos R, Prakash Reddy V. Editorial: Metabolic Disorders, Drug Development, Drug Design and Biomarkers. Curr Pharm Des. 2015 Dec 27.
  • Del Coso J1, Lara B1, Salinero JJ1, Areces F1, Ruiz-Vicente D1, Gallo-Salazar C1, Abián-Vicén J1, Cacabelos R2. CFTR genotype-related body water and electrolyte balance during a marathon. Scand J Med Sci Sports. 2015 Aug 17. doi: 10.1111/sms.12542.
  • Cacabelos R, Cacabelos P, Torrellas C, Carrera I. Inmunoterapia en la enfermedad de Alzheimer: Vacunas y Farmacogenómica. Cuadernos de Autoinmunidad 7: 42-54 (2014).
  • Cacabelos, R., Cacabelos, P., Torrellas, C., Tellado, I., Carril, J.C.. Pharmacogenomics of Alzheimer’s disease: novel therapeutic strategies for drug development. Methods Mol Biol 1175: 323-556 (2014).
  • Cacabelos, R., López-Muñoz, F. The ABCB1 transporter in Alzheimer’s disease. Clin Exp Pharmacol 4: e128 (2014).
  • Cacabelos, R., Goldgaber, D., Vostrov, A., Matsuki, H., Torrellas, C., Corzo, D., Carril, J.C., Roses, A.D. APOE-TOMM40 in the Pharmacogenomics of dementia. J Pharmacogenomics Pharmacoproteomics 5: 135 (2014).
  • Siest, G., Medeiros, R., Melichar, B., Stathopoulou, M., Van Schaik, R.H., Cacabelos, R., Abt, P.M., Monteiro, C., Gurwitz, D., Queiroz, J., Mota-Filipe, H., Ndiaye, N.C., Visvikis-Siest, S. Conference scene. Pharmacogenomics: from cell to clinic (Part 1). Pharmacogenomics 15: 593-9 (2014).
  • Siest, G., Medeiros, R., Melichar, B., Stathopoulou, M., Van Schaik, R.H., Cacabelos, R., Abt, P.M., Monteiro, C., Gurwitz, D., Queiroz, J., Mota-Filipe, H., Ndiaye, N.C., Visvikis-Siest, S. Conference scene. Pharmacogenomics: from cell to clinic (Part 2). Pharmacogenomics 15: 739-44 (2014).
  • Torrellas, C., Carril, J.C., Cacabelos, R. Benefits of Pharmacogenetics in the Management of Hipertensión. J Pharmacogenomics Pharmacoproteomics 5: 126 (2014).
  • Cacabelos, R. The pathogenic component of the APOE-TOMM40 region in Alzheimer’s disease: Its implications in Metabolomics and Pharmacogenomics. Metabolomics 4: e129 (2014).
  • Cacabelos, R. Metabolomics of epigenetic drugs: precautionary measures. Metabolomics 4: e126 (2014).
  • Cacabelos, R., Torrellas, C., López-Muñoz, F. Epigenomics of Alzheimer’s disease. J Exp Med 6: 75-82 (2014).
  • Cacabelos, R., Torrellas, C. Epigenetic drug discovery for Alzheimer’s disease. Expert Opin Drug Discov 9: 1059-86 (2014).
  • Cacabelos, R. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics. Drug Dev Res 75: 348-65 (2014).
  • Aliev, G., Priyadarshini, M., Reddy, V.P., Grieg, N.H., Kaminsky, Y., Cacabelos, R., Ashraf, G.M., Jabir, N.R., Kamal, M.A., Nikolenko, V.N., Zamyatnin, A.A., Benberin, V.V., Bachurin, S.O.
  • Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. Curr Med Chem 21: 2208-17 (2014).
  • Cherif, O., Allouche, F., Chabchoub, F., Chioua, M., Soriano, E., Yañez, M., Cacabelos, R., Romero, A., López, M.G., Marco-Contelles, J. Isoxazolotacrines as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer’s disease. Future Med Chem 6: 1883-91 (2014).
  • López-Muñoz, F., Shen, W.W., Álamo, C., Cacabelos, R. Serendipitous discovery of first two antidepressants. Taiwanese Journal of Psychiatry, 28:67-70 (2014)
  • Cacabelos, R., Cacabelos, P., Aliev, G. Genomics and pharmacogenomics of antipsychotic drugs. Open J. Psychiatry 3:46-139 (2013). Doi:10.4236/ojpsych.2013.31008.
  • Romero, A., Cacabelos, R., Oset-Gasque, M.J., Samadi, A., Marco-Contelles, J. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer’s disease. Bioorganic & Medicinal Chemistry Lett., (2013). Doi: http://dx.doi.org/10.1016/j.bmcl.2013.02.017.
  • Carrera, I., Cacabelos, R. Novel immunotherapeutic procedures for prevention of Alzheimer’s disease. Drug Des., 2013, 2:2. http://dx.doi.org/10.4172/2169-0138.1000107.
  • Aliev, G., Obrenovich, M.E., Tabrez, S., Jabir, N.R., Reddy, V.P., Li, Y., Burnstock, G., Cacabelos, R., Kamal, M.A. Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA overproliferation and deletion. Oxidative Medicine and Cellular Longevity (2013). http://dx.doi.org/10.1155/2013/962984.
  • Aliev, G., Palacios, H.H., Cacabelos, P., Cacabelos, R., Burzynski, G., Burzynski, S.R. Mitochondria specific antioxidants and their derivatives in the context of the drug development for neurodegeneration and cancer. Drug Des., (2013), 2:1. http://dx.doi.org/10.4172/2169-0138.1000103.
  • Carrera, I., Etcheverría, I., Li, Y., Fernández-Novoa, L., Lombardi, V., Vigo, C., Palacios, H.H., Benberin, V., Cacabelos, R., Aliev, G. Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid-β vaccine. BioMed Research International (2013). http://dx.doi.org/10.1155/2013/709145
  • Cacabelos, R., Martínez-Bouza, R., Carril, J.C., Fernández-Novoa, L., Lombardi, V., Carrera, I., Corzo, L., McKay, A. Genomics and pharmacogenomics of brain disorders. Current Pharmaceutical Biotechnology 13:674-725 (2012).
  • Lombardi, V.R.M., Etcheverría, I., Carrera, I., Cacabelos, R., Chacón, A. Prevention of chronic experimental colitis induced by dextran sulphate sodium (DSS) in mice treated with FR91. J. Biomed. Biotech., (2012). Doi:10.1155/2012/826178.
  • Cacabelos, R., Martínez, R., Fernández-Novoa, L., Carril, J.C., Lombardi, V., Carrera, I., Corzo, L., Tellado, I., Leszek, J., McKay, A., Takeda, M. Genomics of dementia: APOE- and CYP2D6-related pharmacogenetics. Intern. J. Alzheimer Dis., (2012). Doi:10.1155/2012/518901.
  • Carrera I., Etcheverría, I., Fernández-Novoa, L., Lombardi, V., Cacabelos, R., Vigo, C. Vaccine development to treat Alzheimer’s disease neuropathology in APP/PS1 transgenic mice. Intern. J. Alzheimer Dis., (2012). Doi:10.1155/2012/376138.
  • Canuet, L., Tellado, I., Couceiro, V., Fraile, C., Fernández-Novoa, L., Ishii, R., Takeda, M., Cacabelos, R. Resting-state network disruption and APOE genotype in Alzheimer’s disease: A lagged functional connectivity study. PLoS ONE (2012) 7(9): e46289. Doi:10.1371/journal.pone.0046289.
  • Cacabelos, R. Pharmacogenomics of central nervous system (CNS) drugs. Drug Development Research, 73:461-476 (2012).
  • Cacabelos, R. The metabolomics paradigm of pharmacogenomics in complex disorders. Metabolomics (2012), 2:5. http//dx.doi.org/10.4172/2153-0769.1000e119.
  • Aliev, G., Reddy, V.P., Cacabelos, R. Role of electron microscopy-immunocytochemistry and in situ hybridization in the study of oxidative stress-induced mitochondrial abnormalities and the pathobiology of neurodegeneration and cancer. In: Current Microscopy Contributions to Advances in Science and Technology. Méndez-Vilas, A. (Ed). pp. 366-385 (2012).
  • Cacabelos, R. Genomics of psychosis. Gen-T (EuroEspes J Int Ed) 3:3 (2011).
  • Cacabelos, R., Fernández-Novoa, L., Lombardi, V., Carril, J.C., Corzo, L., Carrera, I., Tellado, I., Martínez, R., McKay, A., Takeda, M. Genomics of schizophrenia and psychotic disorders. Gen-T (EuroEspes J Int Ed) 3:6-86 (2011).
  • Carril, J.C., Martínez-Bouza, R., Fernández-Novoa, L., Carrera, I., Corzo, L., Fraile, C., Tellado, I., McKay, A., Bello, A., Lombardi, V., Cacabelos, R. The EuroEspes Pharmacogenetic Card. Personalization of pharmacological treatment. Gen-T (EuroEspes J Int Ed) 3:88-118 (2011).
  • Carrera, I., Lombardi, V.R.M., Etcheverría, I., Martínez, E., Chacón, R., Cacabelos, R. Prevención de colitis experimental crónica inducida por dextrán sulfato sódico (DSS) en ratones tratados con FR-91. Gen-T 7:19-30 (2011).
  • Cacabelos, R., Martínez-Bouza, R., Tellado, I., Alcaraz, M., Nebril, L., Casas, A., González, Y., López, L., Couceiro, V., Fraile, C., Rodríguez, S., Corzo, L., Carril, J.C., Lombardi, V., Carrera, I., Fernández-Novoa, L. Gen-T 7:42-74 (2011).
  • Carrera, I., Etcheverría, I., Fernández-Novoa, L., Lombardi, V., Vigo, C., Cacabelos, R. Desarrollo de la vacuna EuroEspes EB101 contra la enfermedad de Alzheimer. Gen-T 8: 38-52 (2011).
  • Cacabelos, R. Alzheimer’s disease 2011: Where are we heading. Gen-T 8:54-86 (2011).
  • Cacabelos, R. Pharmacogenomics of Alzheimer’s disease. Metabolomics 1:3, 1000106e (2011). http://dx.doi.org/10.4172/2153-0769.1000106e.
  • Alvarez, X.A., Cacabelos, R., Sampedro, C., Couceiro, V., Aleixandre, M., Vargas, M., Linares, C., Granizo, E., García-Fantini, M., Baurecht, W., Doppler, E., Moessler, H. Combination treatment in Alzheimer’s disease: Results of a randomized, controlled trial with cerebrolysin and donepezil. Cur Alzheimer Res 8:583-591 (2011).
  • Alvarez, X.A., Cacabelos, R., Sampedro, C., Aleixandre, M., Linares, C., Granizo, E., Doppler, E., Moessler, H. Efficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, doubled-blind, controlled trial investigating three dosages of cerebrolysin. Eur J Neurol 18:59-68 (2011).
  • Cacabelos, R., Hashimoto, R., Takeda, M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiat Clin Neurosci 65:3-19 (2011)
  • Cacabelos, R. Pharmacogenomic protocols in CNS disorders and dementia. Neurodegenerative Dis., 7:167-169 (2010).
  • Cacabelos, R., Martínez-Bouza, R. Genomics and pharmacogenomics of schizophrenia. CNS Neuroscience & Therapeutics. DOI: 10.111_j.1755-5949.2010.00187.
  • Cacabelos, R., Martínez-Bouza, R. Genomics and pharmacogenomics of dementia. CNS Neurosciences & Therapeutics. DOI: 10.111_j.1755-5949.2010.00189.
  • Cacabelos, R., Fernández-Novoa, L., Martínez-Bouza, R., McKay, A., Carril, J.C., Lombardi, V., Corzo, L., Carrera, I., Tellado, I., Nebril, L., Alcaraz, M., Rodríguez, S., Casas, A., Couceiro, V., Alvarez, A. Future trends in the pharmacogenomics of brain disorders and dementia: Influence of APOE and CYP2D6 variants. Pharmaceuticals 3:3040-3100 (2010); doi: 10.3390/ph3103040.
  • Cacabelos, R., Martínez-Bouza, R., Carril, J.C., Fernández-Novoa, L., Llovo, R., Carrera, I., Corzo, L., Fraile, C., Telladi, I., McKay, A., Bello, A., Cacabelos, N., Lombardi, V. Tarjeta Farmacogenética EuroEspes: La personalización del tratamiento farmacológico. Gen-T 5:36-60 (2010).
  • Cacabelos, R., Fernández-Novoa, L., Martínez-Bouza, R., Carril, R., Carrera, I., Fraile, C., Tellado, I., Corzo, L., Lombardi, V. Los genes de la locura. Genómica de la esquizofrenia y los trastornos psicóticos. Gen-T 6:34-57 (2010).
  • Takeda, M., Martínez, R., Kudo, T., Tanaka, T., Okochi, M., Tagami, S., Morihara, T., Hashimoto, R., Cacabelos, R. Apolipoprotein E and central nervous system disorders: Reviews of clinical findings. Psychiat Clin Neurosci 64:592-607 (2010).
  • Lombardi, V.R.M., Cacabelos, R. Neuron-Glia interactions and neurodegeneration. Psychogeriatria Polska 7(4):115-130 (2010)
  • Álvarez, X.A., Sampedro, C., Cacabelos, R., Linares, C., Aleixandre, M., García-Fantini, M., Moessler, H. Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent Cerebrolysin. Int. J. Neuropsychopharmacol., 12:867-872 (2009).
  • Cacabelos, R. Pharmacogenomic Biomarkers in Neuropsychiatry: The Path to Personalized Medicine in Mental Disorders. In: The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. Vol. IV: Molecular Genetic and Genomic Markers. Ritsner, M.S. (Ed.). Springer, pp. 3-63 (2009).
  • Cacabelos, R., Martínez-Bouza, R., Fernández-Novoa, L., Carril, J.C., Llovo, R., Tellado, I., Corzo, L., Fraile, C., Cacabelos, N., Bello, A., McKay, A., Bermo, A., Carrera, I., Álvarez, A., Lombardi, V. Personalized medicine of dementia. Pharmacogenomics of Alzheimer’s disease. Gen-T/The EuroEspes Journal, 4:18-48 (2009).
  • Lombardi, V.R.M., Martínez, E., Chacon, R., Etcheverría, I., Cacabelos, R. Effects of FR-91 on human tumor cell lines. Gen-T/The EuroEspes Journal, 4:50-60 (2009).
  • Cacabelos, R. Pharmacogenomics and therapeutic strategies for dementia. Expert Rev. Mol. Diag., 9:567-611 (2009).
  • Lombardi, V.R.M., Martínez, E., Chacón, R., Etcheverría, I., Cacabelos, R. Effects of FR-91 on immune cells from healthy individuals and from patients with non-Hodgkin lymphoma. J. Biomed. Biotech., DOI: 10.1155/2009/187015 (2009).
  • Harguindey, S., Orive, G., Cacabelos, R., Meléndez Hevia, E., Díaz de Otazu, R., Arranz, J.L., Anitua, E. An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS). Neuropsychiat. Dis. Treat., 4:1073-1087 (2008).
  • Cacabelos, R. Application of nutrigenomics to Alzheimer’s disease. AgroFood, 19:37-40 (2008).
  • Cacabelos, R. Pharmacogenomics and therapeutic prospects in dementia. Eur. Arch. Psychiatry Clin. Neurosci., 258(Suppl. 1):28-47 (2008).
  • Cacabelos, R. Influence of pharmacogenetic factors on Alzheimer’s disease therapeutics. Neurodegenerative Dis., 5:176-178 (2008).
  • Cacabelos, R. Pharmacogenomics in Alzheimer’s disease. Meth Mol. Biol., 448:213-357 (2008).
  • Cacabelos, R. Pharmacogenomics in Alzheimer’s disease. In: Pharmacogenomics and Personalized Medicine. Cohen, N. (Ed.). pp. 317-368 (2008).
  • Cacabelos, R. Pleiotropic effects of Apolipoprotein E in dementia: Influence on functional genomics and pharmacogenetics. Adv. Behav. Biol., 57:355-367 (2008).
  • Álvarez, X.A., Sampedro, C., Figueroa, J., Tellado, I., González, A., García-Fantini, M., Cacabelos, R., Muresanu, D., Moessler, H. Reductions in qEEG slowing over 1 year and after treatment with cerebrolysin in patients with moderate-severe traumatic brain injury. J. Neural Transm., 115:683-692 (2008).
  • Cacabelos, R. Molecular pathology and pharmacogenomics in Alzheimer’s disease: Polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Meth. Find. Exper. Clin. Pharmacol., 29(Supp. A):1-91 (2007).
  • Takeda, M., Cacabelos, R. (Eds.). Alzheimer’s disease genomics. Cognition and Dementia, 6(Suppl.):7-113 (2007).
  • Cacabelos, R. Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics. Neuropsychiat. Dis. Treat., 3:303-333 (2007).
  • Álvarez, A., Cacabelos, R., Sampedro, C., García-Fantini, M., Aleixandre, M. Serum TNF-alpha levels are increased and correlate negatively with free IGF-1 in Alzheimer’s disease. Neurobiol. Aging, 28:533-536 (2007).
  • Corzo, L., Zas, R., Rodríguez, S., Fernández-Novoa, L., Cacabelos, R. Decreased levels of serum nitric oxide in different forms of dementia. Neurosci. Lett., 420:263-267 (2007).
  • Cacabelos, R (Ed.). Cholinesterase inhibitors in Dementia. Ten years of Donepezil in Alzheimer’s Disease and CNS Disorders (1996-2006): Therapeutic Assessment and Pharmacogenetics. Gen-T/The EuroEspes Journal, Suppl. 1:1-52 (2007).
  • Cacabelos, R., Llovo, R., Fraile, C., Fernández-Novoa, L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimer’s disease pharmacogenetics. Cur. Alzheimer Res., 4:479-500 (2007).
  • Cacabelos, R. Pharmacogenetic basis for therapeutic optimization in Alzheimer’s disease. Mol. Diag. Ther., 11:385-405 (2007).
  • Takeda, M., Cacabelos, R., Ray, O., Förstl, H., Hoon Oh, B. Dementia in the World. Cogn. Dementia, 2:53-63 (2007).
  • Cacabelos, R. Homocysteine and cognition: from Galenic dogmatism to genetic relativism. Aging Health, 2:783-786 (2006).
  • Álvarez, X.A., Cacabelos, R., Laredo, M., Couceiro, V., Sampedro, C., Varela, M., Corzo, L., Fernández-Novoa, L., Vargas, M., Aleixandre, M., Linares, C., Granizo, E., Muresanu, D., Moessler, H. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Eur. J. Neurol., 13:43-54 (2006).
  • Cacabelos, R., Takeda, M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimer’s disease. Drugs Future, 31(Suppl. B):5-146 (2006).
  • Isaza, C., Henao, J., Ramírez, E., Cuesta, F., Cacabelos, R. Polymorphic variants of the beta-2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population. Meth. Find. Exp. Clin. Pharmacol., 27:237-244 (2005).
  • Cacabelos, R. Función cerebrovascular en la enfermedad de Alzheimer (2005) www.sinapsis.org/.
  • Lombardi, V.R.M., Fernández-Novoa, L., Etcheverría, I., Seoane, S., Cacabelos, R. Effects of fish-derived lipoprotein extracts on activation markers, Fas expression and apoptosis in peripheral blood lymphocytes. Intern. Immunopharmacol., 5:253-262 (2005).
  • Cacabelos, R., Kubota, Y., Isaza, C., Henao, J., Fernández-Novoa, L., Lombardi, V.R.M., Corzo, L., Pichel, V. Functional genomics and pharmacogenetics in Alzheimer’s disease. In: Recent Progress in Alzheimer’s and Parkinson’s Diseases. Hanin, I., Cacabelos, R., Fisher, A. (Eds.). Taylor & Francis, London, pp. 89-102 (2005).
  • Lombardi, V.R.M., Fernández-Novoa, L., Etcheverría, I., Seoane, S., Cacabelos, R. Regulating factors for microglial activation: implication for Alzheimer’s disease and brain damage. In: Recent Progress in Alzheimer’s and Parkinson’s Diseases. Hanin, I., Cacabelos, R., Fisher, A. (Eds.). Taylor & Francis, London, pp. 171-176 (2005).
  • Cacabelos, R., Fernández-Novoa, L., Lombardi, V., Kubota, Y., Takeda, M. Molecular genetics of Alzheimer’s disease and aging. Meth. Find. Exp. Clin. Pharmacol., 27(Suppl. A):1-573 (2005).
  • Cacabelos, R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimer’s disease. Aging Health, 1:303-348 (2005).
  • Cacabelos, R. Pharmacogenomics and therapeutic prospects in Alzheimer’s disease. Expert Opin. Pharmacother., 6:1967-1987 (2005).
  • Cacabelos, R. Role of nutrition in the prevention of Alzheimer’s disease. Aging Health, 1:359-362 (2005).
  • Álvarez, X.A., Corzo, L., Laredo, M., Sampedro, C., Cacabelos, R., Windisch, M., Moessler, H., Crook, T.H. Neuropeptide dietary supplement N-PEP-12 enhances cognitive function and activates brain bioelectrical activity in healthy elderly subjects. Meth. Find. Exper. Clin. Pharmacol., 27:493-487 (2005).
  • Lombardi, V.R.M., Fernández-Novoa, L., Etcheverría, I., Seoane, S., Cacabelos, R. Association between APOE-4 allele and increased expression of CD95 on T cells from patients with Alzheimer’s disease. Meth. Find. Exp. Clin. Pharmacol., 26:523-529 (2004).
  • Cacabelos, R., Corzo, L., Fernández-Novoa, L., Lombardi, V. Histamine in Alzheimer’s disease pathogenesis: Biochemistry and functional genomics. Meth. Find. Exp. Clin. Pharmacol., 26(Suppl. 2):9-16 (2004).
  • Cacabelos, R., Vallejo, A.I., Lombardi, V., Fernández-Novoa, L., Pichel, V. E-SAR-94010 (LipoEsar®): A pleiotropic lipoprotein compound with powerful anti-atheromatous and lipid lowering effects. CNS Drug Rev., 10:200-201 (2004).
  • Cacabelos, R., Fernández-Novoa, L., Corzo, L., Pichel, V., Lombardi, V., Kubota, Y. Genomics and phenotypic profiles in dementia: Implications for pharmacological treatment. Meth. Find. Exp. Clin. Pharmacol., 26:421-444 (2004).
  • Cacabelos, R., Fernández-Novoa, L., Corzo, L., Amado, L., Pichel, V., Lombardi, V., Kubota, Y. Phenotypic profiles and functional genomics in Alzheimer’s disease and in dementia with a vascular component. Neurol. Res., 26:459-480 (2004).
  • Cacabelos, R. Genomic characterization of Alzheimer’s disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics, 5:1049-1105 (2004).
  • Cacabelos, R., Fernández-Novoa, L., Pichel, V., Lombardi, V., Kubota, Y., Takeda, M. Pharmacogenomic studies with a combination therapy in Alzheimer’s disease. In: Molecular Neurobiology of Alzheimer’s Disease and Related Disorders. Takeda, M., Tanaka, T., Cacabelos, R. (Eds.). Karger, Basel, pp. 94-107 (2004).
  • Cacabelos, R., Lombardi, V., Fernández-Novoa, L., Kubota, Y., Corzo, L., Pichel, V., Takeda, M. A functional genomics approach to the analysis of biological markers in Alzheimer disease. In: Molecular Neurobiology of Alzheimer’s Disease and Related Disorders. Takeda, M., Tanaka, T., Cacabelos, R. (Eds.). Karger, Basel, pp. 236-285 (2004).
  • Takeda, M., Cacabelos, R., Ray, O., Förstl, H., Hoon Oh, B. International perspective on the diagnosis and treatment of dementia. Cognition & Dementia, 2:53-63 (2003).
  • Takeda, M., Okochi, M., Sugaya, K., De-Maw, C., Hashimoto, R., Kuroda, S., Shinosaka, K., Kudo, T., Tanaka, T., Cacabelos, R. Research strategy for understanding neuronal plasticity and degeneration. Seishin Shinkeigaku Zasshi, 105:43-46 (2003).
  • Cacabelos, R., Fernández-Novoa, L., Lombardi, V., Takeda, M. Genetic variation and pharmacogenomics in Alzheimer disease. Psychiat. Neurol. Jap., 105:47-67 (2003).
  • Lombardi, V.R.M., Etcheverría, I., Fernández-Novoa, L., Cacabelos, R. In vitro regulation of rat-derived microglia. Neurotox. Res., 5:201-212 (2003).
  • Lombardi, V.R.M., Etcheverría, I., Fernández-Novoa, L., Blanco, A., Díaz, J., Cacabelos, R. Extracts from Polypodium ferns upregulate the expression of CD95 in human peripheral blood lymphocytes. Orient. Pharm. Exper. Med., 3:90-99 (2003).
  • Álvarez, X.A., Sampedro, C., Pérez, P., Laredo, M., Couceiro, V., Hernández, A., Figueroa, J., Varela, M., Arias, D., Corzo, L., Zas, R., Lombardi, V., Fernández-Novoa, L., Pichel, V., Cacabelos, R., Windisch, M., Aleixandre, M., Moessler, H. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. Intern. Clin. Psychopharmacol., 18:271-278 (2003).
  • Cacabelos, R. The application of functional genomics to Alzheimer’s disease. Pharmacogenomics, 4:597-621 (2003).
  • Isaza, C., Henao, J., López, A.M., Cacabelos, R. Allelic variants of the thiopurine methyltransferase (TPMT) gene in the Colombian population. Meth. Find. Exp. Clin. Pharmacol., 25:423-429 (2003).
  • Cacabelos, R., Fernández-Novoa, L., Lombardi, V., Corzo, L., Pichel, V., Kubota, Y. Cerebrovascular risk factors in Alzheimer’s disease: Brain hemodynamics and pharmacogenomic implications. Neurol. Res., 25:567-580 (2003).
  • Lombardi, V.R.M., Fernández-Novoa, L., Cacabelos, R. Neuroglia and neurotrophic factors (NTFs): potential targets for future therapeutics. Current Topics in Pharmacology, 7:229-246 (2003).
  • Pichel, V., Etcheverría, I., Amado, L., Kubota, Y., Cacabelos, R. Cerebrovascular risk factors and brain hemodynamics in dementia. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 23-27 (2003).
  • Lombardi, V.R.M., Amado, L., Fernández-Novoa, L., Etcheverría, I., Seoane, S., Cacabelos, R. Flow cytometry analysis of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of Alzheimer’s disease patients. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 57-61 (2003).
  • Corzo, L., Zas, R., Fernández-Novoa, L., Cacabelos, R. SERUM nitric oxide in Alzheimer disease. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 63-68 (2003).
  • Kubota, Y., Pichel, V., Fernández-Novoa, L., Cacabelos, R. Combination therapy in Alzheimer disease: a pharmacogenomic study. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 87-90 (2003).
  • Etcheverría, I., Pichel, V., Amado, L., Fernández-Novoa, L., Lombardi, V., Cacabelos, R. APOE genotype-related brain atrophy in the Spanish population. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 91-96 (2003).
  • Fernández-Novoa, L., Lombardi, V.R.M., Seoane, S., Etcheverría, I., Corzo, L., Cacabelos, R. The ACE gene in Alzheimer’s disease. In: Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, pp. 123-126 (2003).
  • Cacabelos, R. Pharmacogenomics in Alzheimer’s disease. Min. Rev. Medic. Chem., 2:59-84 (2002).
  • Cacabelos, R. Pharmacogenomics for the treatment of dementia. Ann. Med., 34:357-379 (2002).
  • Lombardi, V.R.M., Fernández-Novoa, L., Corzo, D., Zas, R., Cacabelos, R. Enhancement in immune function and growth using E-JUR-94013 supplementation. Meth. Find. Exp. Clin. Pharmacol., 24:573-578 (2002).
  • Miguel-Hidalgo, J.J., Álvarez, X.A., Cacabelos, R., Quack, G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res., 958:210-221 (2002).
  • Cacabelos, R. The histamine-citokine network in Alzheimer disease: Etiopathogenic and pharmacogenomic implications. In: Mapping the Progress of Alzheimer’s and Parkinson’s Disease. Mizuno, Y., Fisher, A., Hanin, I. (Eds.). Advances in Behavioral Biology, 51:59-64 (2002).
  • Cacabelos, R. Psychogeriatric research: A conceptual introduction to aging and geriatric neuroscience. Psychogeriatrics, 1:158-188 (2001).
  • Allison, A.C., Cacabelos, R., Lombardi, V.R.M., Álvarez, X.A., Vigo, C. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer’s disease. Prog. Neuro-Psychopharmacol. Biol. Psychiat., 25:1341-1357 (2001).
  • Cacabelos, R., Santamaría, J.L. Hipertensión y Demencia. Mecanismos etiopatogénicos y factores genéticos. Hipertensión Clínica, IV/3:626-659 (2001).
  • Fernández-Novoa, L., Cacabelos, R. Histamine function in brain disorders. Behav. Brain Res., 124:213-233 (2001).
  • Cacabelos, R. Enfermedad de Alzheimer. Presente terapéutico y retos futuros (I). Rev. Colomb. Psiquiatría, XXX/3:215-238 (2001).
  • Cacabelos, R. Enfermedad de Alzheimer. Presente terapéutico y retos futuros (II). Rev. Colomb. Psiquiatría, XXX/4:323-350 (2001).
  • Lombardi, V.R.M., Cagiao, A., Fernández-Novoa, L., Álvarez, X.A., Corzo, M.D., Zas, R., Sampedro, C., Cacabelos, R. Short term food supplementation effects of a fish derived extract on the immunological status of pregnant rats and their sucking pups. Nutrition Res., 21:1425-1434 (2001).
  • Allison, A.C., Cacabelos, R., Lombardi, V.R.M., Álvarez, X.A., Vigo, C. Central nervous system effects of Celastrol, a potent antioxidant and antiinflammatory agent. CNS Drug Rev., 6:45-62 (2000).
  • Álvarez, X.A., Lombardi, V.R.M., Fernández-Novoa, L., García, M., Sampedro, C., Cagiao, A., Cacabelos, R., Windisch, M. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. J. Neural Transm., 59:281-292 (2000).
  • Álvarez, X.A., Lombardi, V.R.M., Corzo, L., Pérez, P., Pichel, V., Laredo, M., Hernández, A., Freixeiro, F., Sampedro, C., Lorenzo, R., Alcaraz, M., Windisch, M., Cacabelos, R. Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects. J. Neural Transm., 59:315-328 (2000).
  • Cacabelos, R., Álvarez, X.A., Lombardi, V., Fernández-Novoa, L., Corzo, L., Pérez, P., Laredo, M., Pichel, V., Hernández, A., Varela, M., Figueroa, J., Prous Jr. J., Windisch, M., Vigo, C. Pharmacological treatment of Alzheimer disease: From psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today, 36:415-499 (2000).
  • Cacabelos, R. Pharmacogenomics in Alzheimer’s disease. Drug News Perspect., 13:252-254 (2000).
  • Álvarez, X.A., Pichel, V., Pérez, P., Laredo, M., Corzo, D., Zas, R., Fernández-Novoa, L., Sempere, J.M., Díaz, J., Cacabelos, R. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: Effects on cognition, brain bioelectrical activity and cerebral hemodynamics. Meth. Find. Exp. Clin. Pharmacol., 22:585-594 (2000).
  • Cacabelos, R., Álvarez, X.A., Fernández-Novoa, L., Lombardi, V.R.M. A pharmacogenomic approach to Alzheimer’s disease. Acta Neurol. Scand., 102(Suppl. 176):12-19 (2000).
  • Isaza, C.A., Henao, J., López, A.M., Cacabelos, R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Meth. Find. Exp. Clin. Pharmacol., 22:695-705 (2000).
  • Cacabelos, R., Beyer, K., Lao, J.I., Mesa, M.D., Fernández-Novoa, L. Association of genetic risk factors in Alzheimer’s disease and a novel mutation in the predicted TM2 domain of presenilin-2 in late-onset AD. In: Alzheimer’s Disease and Related Disorders. Iqbal, K., Swaab, D.F., Winblad, B., Wisniewski, H.M. (Eds.). John Wiley & Sons, Chichester, pp. 93-102 (1999).
  • Lombardi, V.R.M., Cacabelos, R. 19/20 kDa low molecular weight serum protein pattern: a novel potential biochemical prognostic marker for different types of dementia. Neurosci. Lett., 260:61-64 (1999).
  • Lombardi, V.R.M., Cacabelos, R. E-SAR-94010: A marine fish extract obtained by advanced biotechnological methods. Drugs Future, 24:167-176 (1999).
  • Cacabelos, R., Takeda, M., Winblad, B. The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer’s disease. Int. J. Geriat. Psychiatry, 14:3-47 (1999).
  • Lombardi, V.R.M., Windisch, M., García, M., Cacabelos, R. Effects of cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures. Meth. Find. Exp. Clin. Pharmacol., 21:331-338 (1999).
  • Cacabelos, R. The search for new health care models, integrated treatments and prevention for dementia. Ann. Psychiatry, 7:XVII-XX (1999).
  • Mesa, M.D., Fernández-Novoa, L., Cacabelos, R. Association of genetic risk factors in Alzheimer’s disease. Ann. Psychiatry, 7:35-45 (1999).
  • Laredo, M., Álvarez, X.A., Pérez, P., Cacabelos, R. Psychometric evaluation and apolipoprotein E genotyping in senile dementia. Ann. Psychiatry, 7:67-75 (1999).
  • Pérez, P., Álvarez, X.A., Laredo, M., Pichel, V., Cacabelos, R. Brain electrical activity mapping, disease staging and apolipoprotein E genotyping in senile dementia. Ann. Psychiatry, 7:77-85 (1999).
  • Pichel, V.M., Caamaño, J.M., Figueroa, J., Hernández, A., Álvarez, X.A., Pérez, P., Laredo, M., Cacabelos, R. Changes in brain hemodynamic parameters associated with disease staging and apolipoprotein E genotyping in patients with senile dementia. Ann. Psychiatry, 7:87-92 (1999).
  • Mouzo, R., Álvarez, X.A., Pichel, V.M., Alcaraz, M., Cacabelos, R. Apolipoprotein E-related blood pressure parameters in senile dementia. Ann. Psychiatry, 7:93-97 (1999).
  • Corzo, L., Fernández-Novoa, L., Zas, R., Laredo, M., Alcaraz, M., Álvarez, X.A., Cacabelos, R. Apolipoprotein E genotype-related serum apolipoprotein E and lipid levels in Alzheimer’s disease. Ann. Psychiatry, 7:99-107 (1999).
  • Fernández-Novoa, L., Corzo, L., Zas, R., Laredo, M., Pérez, P., Pichel, V., Mesa, M.D., Cacabelos, R. Blood histamine levels, brain hemodynamic parameters and risk factors in Alzheimer’s disease and vascular dementia. Ann. Psychiatry, 7:109-117 (1999).
  • Álvarez, X.A., Sampedro, C., Cacabelos, R. Antiapoptotic effects of CDP-choline in a combined (A4/hypoperfusion) animal model of hippocampal neurodegeneration. Ann. Psychiatry, 7:147-156 (1999).
  • Lombardi, V.R.M., García, M., Cacabelos, R. Genotype-specific microglial response in cell culture systems for the identification of novel therapeutic compounds in Alzheimer’s disease and neuroimmune disorders. Ann. Psychiatry, 7:157-170 (1999).
  • Cacabelos, R., Álvarez, X.A., Lombardi, V. Alzheimer’s disease: Pharmacoeconomics, glutamate-induced neurodegeneration and preventive strategies. Ann. Psychiatry, 7:195-239 (1999).
  • Lombardi, V.R.M., García, M., Cacabelos, R. Evolution of senescence: Cellular aging, apoptosis, immune surveillance and tumor development. Ann. Psychiatry, 7:279-308 (1999).
  • Álvarez, X.A., Mouzo, R., Pichel, V., Pérez, P., Laredo, M., Fernández-Novoa, L., Corzo, L., Zas, R., Alcaraz, M., Secades, J., Lozano, R., Cacabelos, R. Effects of citicoline on cognitive performance, brain bioelectrical activity and brain hemodynamics in Alzheimer’s disease patients: A double-blind placebo-controlled study. Ann. Psychiatry, 7:331-352 (1999).
  • Álvarez, X.A., Sampedro, C., Lozano, R., Cacabelos, R. Citicoline protects hippocampal neurons against apoptosis induced by brain -amyloid deposits plus cerebral hypoperfusion in rats. Meth. Find. Exp. Clin. Pharmacol., 21:535-540 (1999).
  • Álvarez, X.A., Mouzo, R., Pichel, V., Pérez, P., Laredo, M., Fernández-Novoa, L., Corzo, L., Zas, R., Alcaraz, M., Secades, J.J., Lozano, R., Cacabelos, R. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Meth. Find. Exp. Clin. Pharmacol., 21:633-644 (1999).
  • Álvarez, X.A., Sampedro, C., Cacabelos, R. Citicoline reduces neuronal apoptosis in rats with brain hypoperfusion and hippocampal -amyloid implants. Proc. 1st Int. Cong. Vascular Dementia. Monduzzi Editore, Bologna, pp. 239-243 (1999).
  • Álvarez, X.A., Fernández-Novoa, L., Sampedro, C., Lombardi, V., Windisch, M., Cacabelos, R. Neuroimmunotrophic effects of Cerebrolysin in an animal model of hippocampal degeneration induced by -amyloid. Proc. 1st Int. Cong. Vascular Dementia. Monduzzi Editore, Bologna, pp. 233-237 (1999).
  • de Olano, M., Mesa, M.D., Fernández-Novoa, L., Corzo, L., Blanco, A., Cacabelos, R. Angiotensin-converting enzyme I/D polymorphism and ansiotensinogen M235T polymorphism in cerebrovascular pathology. Proc. 1st Int. Cong. Vascular Dementia. Monduzzi Editore, Bologna, pp. 207-210 (1999).
  • Laredo, M., Couceiro, V., Corzo, L., Pérez, P., Anido, R., Álvarez, X.A., Cacabelos, R. Sleep disorders in vascular dementia and Alzheimer disease. Proc. 1st Int. Cong. Vascular Dementia. Monduzzi Editore, Bologna, pp. 129-133 (1999).
  • Lombardi, V.R., García, M., Rey, L., Cacabelos, R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer’s disease individuals. J. Neuroimmunol., 97:163-171 (1999)
  • Cacabelos, R. Etiopatogenia del deterioro cognitivo. Factores de riesgo de los trastornos de memoria. Prensa Médica Argentina, 85:176-177 (1998).
  • Cacabelos, R. Tratamiento del deterioro de la memoria y el déficit cognitivo. Prensa Médica Argentina, 85:179-180 (1998).
  • Cacabelos, R. Neuroimmune reactions and inflammatory mechanisms in Alzheimer’s disease: gene-specific responses in therapeutics and prevention. Neurogerontol. Neurogeriat., 2:IX-XII (1998).
  • Maneiro, E., Lombardi, V., Cacabelos, R. Neuroimmune dysfunction in Alzheimer’s disease. Influence of -amyloid, interleukin-l, histamine, and APOE-related sera from patients with Alzheimer’s disease on microglial cells. Neurogerontol. Neurogeriat., 2:77-104 (1998).
  • Lombardi, V., Cacabelos, R. Apoptosis in neurodegenerative diseases: The neuroimmune network. Neurogerontol. Neurogeriat., 2:105-124 (1998).
  • Álvarez, X.A., Miguel, J.J., Fernández-Novoa, L., Díaz, J., Sempere, J.M., Cacabelos, R. Therapeutic agents with potential amyloid scavenging activity: Neuroimmune-associated mechanisms. Neurogerontol. Neurogeriat., 2:141-163 (1998).
  • Cacabelos, R., Pérez del Tío, L., Sellers, A. Caregivers’ perception on dementia-associated social, economic and health problems: Sociodemographic study in the Spanish population. Jap. J. Geriat. Psychiat., 9:133-139 (1998).
  • Miguel-Hidalgo, J.J., Álvarez, A., Cacabelos, R. Plasticity of Congo red staining displayed by subpopulations of neurons within the rat central nervous system. Cell Tiss. Res., 293:75-86 (1998).
  • Miguel-Hidalgo, J.J., Cacabelos, R. -Amyloid (l-40)-induced neurodegeneration in the rat hippocampal neurons of the CA1 subfield. Acta Neuropathol., 95:455-465 (1998).
  • Miguel-Hidalgo, J.J., Vecino, B., Fernández-Novoa, L., Álvarez, A., Cacabelos, R. Neuroprotective role of S12024 against neurodegeneration in the rat dentate gyrus. Eur. Neuropsychopharmacol., 8:203-208 (1998).
  • European Concerted Action on Pick’s Disease (ECAPD) Consortium. Álvarez, X.A., Baker, S., Binetti, G., Boller, F., Bracco, L., Breteler, M., Brun, A., Cacabelos, R., Cairns, N., Cappa, S., Cipolotti, T., Collinge, J., Englund, E., Forleo, P., Förstl, H., Grassi, E., Harvey, R., Hodges, J., Gustafson, L., Kurz, A., Lantos, P., Lauten-Schlager, N., Lebert, F., Muggia, S., Pasquier, F., Passant, V., Ravid, R., Rossor, M., Sorbi, S., Spinnler, H., Stevens, J, van Swieten, J., Warrington, E., Xuereb, J. Provisional clinical and neuroradiological criteria for the diagnosis of Pick’s disease. Eur. J. Neurol., 5:519-520 (1998).
  • Lombardi, V.R.M., Garcia, M., Cacabelos, R. APOE-induced microglial activation: An in vitro assay to screen sera from Alzheimer’s disease patients and novel therapeutic compounds. Meth. Find. Exp. Clin. Pharmacol., 20:377-386 (1998).
  • Lombardi, V.R.M., García, M., Cacabelos, R. Microglial activation induced by factor(s) contained in sera from Alzheimer-related ApoE genotypes. J. Neurosc. Res., 54:539-553 (1998).
  • Cacabelos, R. Bioética asistencial del anciano con enfermedad neurodegenerativa y prevención genética de la demencia. Bioética y Ciencias de la Salud, 3:35-40 (1998).
  • Lao, J.I., Beyer, K., Fernández-Novoa, L., Cacabelos, R. A novel mutation in the predicted TM2 domain of presenilin 2 gene in Spanish patient with late-onset Alzheimer’s disease. Neurogenetics, 1:293-296 (1998).
  • Sellers, A., Pérez, L., Carrera, C., Bustos, J.C., Caamaño, J.M., Rodríguez, B., Mouzo, R., Pérez, P., Lao, J.I., Beyer, K., Álvarez, X.A., Cacabelos, R. Cognitive and non-cognitive symptoms in senile dementia. In: Progress in Alzheimer’s and Parkinson’s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 317-322 (1998).
  • Sellers, A., Pérez, L., Rodríguez, B., Pichel, V.M., Caamaño, J.M., Laredo, M., Alcaraz, M., Álvarez, X.A., Cacabelos, R. Dementia-associated sleep disorders. In: Progress in Alzheimer’s and Parkinson’s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 323-327 (1998).
  • Álvarez, A., Miguel-Hidalgo, J.J., Fernández-Novoa, L., Díaz, J., Sempere, J.M., Cacabelos, R. Anapsos improves learning and memory in rats with A(1-28) deposits into the hippocampus. In: Progress in Alzheimer’s and Parkinson’s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 699-703 (1998).
  • Miguel-Hidalgo, J.J., Álvarez, X.A., Cacabelos, R. In vivo neurotoxicity of -amyloid 1-40 in the rat hippocampus. In: Progress in Alzheimer’s and Parkinson’s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 705-709 (1998).
  • Corzo, L., Fernández-Novoa, L., Zas, R., Beyer, K., Lao, J.I., Álvarez, X.A., Cacabelos, R. Influence of the APOE-genotype on serum ApoE levels in Alzheimer’s disease patients. In: Progress in Alzheimer’s and Parkinson’s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 765-771 (1998).
  • Lao, J.I., Beyer, K., Cacabelos, R. Centromeric disturbances affecting all chromosomes of cultured lymphocytes obtained from Alzheimer’s disease patients. In: Progress in Alzheimer’s and Parkinson’s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 793-798.
  • Mouzo, R., Álvarez, X.A., Pichel, V.M., Sellers, A., Caamaño, J.M., Laredo, M., Beyer, K., Lao, J.I., Pérez, P., Alcaraz, M., Rúa, M.C., Corzo, L., Fernández-Novoa, L., Fernández, R., Cacabelos, R. APOE genotype-related blood pressure in senile dementia. In: Progress in Alzheimer’s and Parkinson’s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 799-803 (1998).
  • Pichel, V.M., Caamaño, J.M., Sellers, A., Mouzo, R., Álvarez, X.A., Pérez, P., Laredo, M., Cacabelos, R. Changes in cerebral blood flow associated with disease staging and APOE genotyping in patients with senile dementia. In: Progress in Alzheimer’s and Parkinson’s diseases. Fisher, A., Hanin, I., Yoshida, M. (Eds.). Plenum Press, New York, pp. 811-815 (1998).
  • Cacabelos, R. Enfermedad de Alzheimer: Bases etiopatogénicas. En: Salud Mental y Psiquiatría en el Umbral del Nuevo Milenio. Asociación Psiquiátrica Peruana y Asociación Psiquiátrica de América Latina. Lima, Perú, pp. 111-134 (1998).
  • Beyer, K., Lao-Villadóniga, J.I., Vecino-Bilbao, B., Cacabelos, R., de la Fuente, R. A novel point mutation in the GTP cyclohydrolase I gene in a Spanish family with hereditary progressive and dopa responsive dystonia. J. Neurol. Neurosurg. Psychiat., 62:420-421 (1997).
  • Miguel-Hidalgo, J.J., Cacabelos, R. Modeling neuronal degeneration in the rodent hippocampus: An approach for studying degenerative neuropathology in dementia. Meth. Find. Exp. Clin. Pharmacol., 19:133-142 (1997).
  • Maneiro, E., Lombardi, V.R.M., Lagares, R., Cacabelos, R. An experimental model to study the cytotoxic effects induced by -amyloid, histamine, LPS and serum from Alzheimer patients on rat cultured endothelial cells. Meth. Find. Exp. Clin. Pharmacol., 19:5-12 (1997).
  • Cacabelos, R. Enfermedad de Alzheimer: Diagnóstico molecular y futuro terapéutico. An. Med. Interna, 14(Supl. 1):72-74 (1997).
  • Álvarez, X.A., Laredo, M., Corzo, D., Fernández-Novoa, L., Mouzo, R., Perea, E., Daniele, D., Cacabelos, R. Citicoline improves memory performance in elderly subjects. Meth. Find. Exp. Clin. Pharmacol., 19:201-210 (1997).
  • Beyer, K., Lao, J.I., Álvarez, X.A., Cacabelos, R. A general method for DNA polymorphism identification in genetic assessment and molecular diagnosis. Meth. Find. Exp. Clin. Pharmacol., 19:87-91 (1997).
  • Fernández-Novoa, L., Álvarez, X.A., Sempere, J.M., Miguel-Hidalgo, J.J., Díaz, J., Franco-Maside, A., Cacabelos, R. Effects of anapsos on the activity of the enzyme Cu-Zn-superoxide dismutase in an animal model of neuronal degeneration. Meth. Find. Exp. Clin. Pharmacol., 19:99-106 (1997).
  • Álvarez, X.A., Zas, R., Fernández-Novoa, L., García, M., Polo, E., Detolle-Sarbach, S., Guez, D., Cacabelos, R. Comparative effects of S9977-2 versus tacrine on passive avoidance learning and psychomotor activity. Hum. Psychopharmacol. Clin. Exp., 12:329-335 (1997).
  • Álvarez, X.A., Franco-Maside, A., Zas, R., Sempere, J.M., Díaz, J., Cacabelos, R. Anapsos reverses interleukin-1 overexpression and behavioral deficits in nbM-lesioned rats. Meth. Find. Exp. Clin. Pharmacol., 19:299-309 (1997).
  • Sellers, M.A., Pérez, L., Cacabelos, R. Evaluación neuropsicológica de la demencia senil en atención primaria. Formación Médica Continuada en Atención Primaria, 4:150-173 (1997).
  • Cacabelos, R., Rodríguez, B., Carrera, C., Beyer, K., Lao, J.I., Sellers, M.A. Behavioral changes associated with different apolipoprotein E genotypes in dementia. Alzheimer’s Dis. Assoc. Dis., 11(Suppl. 4):S27-S37 (1997).
  • Álvarez, X.A., Miguel-Hidalgo, J.J., Fernández-Novoa, L., Díaz, J., Sempere, J.M., Cacabelos, R. Anapsos: Neuroimmunotrophic treatment in Alzheimer’s disease and neurodegenerative disorders. CNS Drug Rev., 3:181-206 (1997).
  • Lao, J.I., Beyer, K., Cacabelos, R. La genética molecular aplicada al diagnóstico de la enfermedad de Alzheimer. Informaciones Psiquiátricas, 147:15-33 (1997).
  • Fernández-Novoa, L., Corzo, L., Zas, R., Álvarez, X.A., Cacabelos, R. Global Deterioration Scale-related brain hemodynamics and histamine levels in Alzheimer’s disease and vascular dementia. Ann. New York Acad. Sci., 826:396-400 (1997).
  • Álvarez, X.A., Fernández-Novoa, L., Caamaño, J., Corzo, L., Zas, R., Beyer, K., Lao, J.I., Cacabelos, R. Cerebrovascular changes associated with interleukin-1 (IL-1) and histamine levels in Alzheimer’s disease. Ann. New York Acad. Sci., 826:375-378 (1997).
  • Beyer, K., Lao, J.I., Fernández-Novoa, L., Álvarez, X.A., Sellers, M.A., Cacabelos, R. APOE-4 allele frequency in Alzheimer’s disease and vascular dementia in the Spanish population. Ann. New York Acad. Sci., 826:452-455 (1997).
  • Álvarez, X.A., Miguel-Hidalgo, J.J., Fernández-Novoa, L., Cacabelos, R. Intrahippocampal injections of the -amyloid 1-28 fragment induce behavioral deficits in rats. Meth. Find. Exp. Clin. Pharmacol., 19:471-479 (1997).
  • Álvarez, X.A., Vecino, B., Perea, J.E., Daniele, D., Cacabelos, R. Citicoline antagonizes bromazepam-induced amnesia in rats. Hum. Psychopharmacol., 12:547-556 (1997).
  • Cacabelos, R. Alzheimer’s disease: Present and future. J. Autonomic Pharmacol., 17:282 (1997).
  • Cacabelos, R., Lao, J.I., Beyer, K., Álvarez, X.A., Franco-Maside, A. Genetic testing in Alzheimer’s disease: ApoE genotyping and etiopathogenic factors. Meth. Find. Exper. Clin. Pharmacol., 18(Suppl. A):161-179 (1996).
  • Cacabelos, R. Clinical Neurosciences and Alzheimer’s disease. Clin. Sci., 90:1 53-156 (1996).
  • Cacabelos, R., Caamaño, J., Gómez, M.J., Fernández-Novoa, L., Franco-Maside, A., Álvarez, X.A. Therapeutic effects of CDP-choline in Alzheimer’s disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. In: Neurobiology of Alzheimer’s disease. Wurtman, R.J., Corkin, S., Growdon, J.H., Nitsch, R.M. (Eds.). Ann. New York Acad. Sci., 777:399-403 (1996).
  • Cacabelos, R. Diagnosis of Alzheimer’s disease: Defining genetic profiles (genotype vs. phenotype). Acta Neurol. Scand. Suppl., 165:72-84 (1996).
  • Cacabelos, R. Enfermedad de Alzheimer. Informaciones Psiquiátricas, 142:443-456 (1995).
  • Fernández-Novoa, L., Álvarez, X.A., Detólle-Sarbanch, S., Guez, D., Zas, R., Polo, E., Cacabelos, R. Effects of S-9977-2 on histamine levels in rats. Meth. Find. Exp. Clin. Pharmacol., 18;197-203 (1996).
  • Vázquez, J., Fernández-Shaw, C., Marina, A., Haas, C., Cacabelos, R., Valdivieso, F. Antibodies to human spectrin in Alzheimer’s disease. J. Neuroimmunol., 68:39-44 (1996).
  • Lombardi, V.R.M., Miguel-Hidalgo, J.J., Mancino, G., Maneiro, E., Poccia, F., Plácido, R., Lagares, R., Cacabelos, R. Apoptosis during HIV infection and in neurodegenerative disorders. Meth. Find. Exp. Clin. Pharmacol., 18:539-555 (1996).
  • Maneiro, E., Lombardi, V.R.M., Cacabelos, R. Rat cell cultures: Experimental models to study neurodegenerative disorders and new pharmacological compounds. Meth. Find. Exp. Clin. Pharmacol., 18:615-645 (1996).
  • Cacabelos, R. Progress in neuropsychiatric disorders and Alzheimer’s disease. Ann. Psychiat., 6:XIII- XIV (1996).
  • Álvarez, X.A., Ayuso-Gutiérrez, J.L., Cacabelos, R. Somatotropinergic system: neurobiology and effects on brain activity and mental functions. Ann. Psychiat., 6:73-104 (1996).
  • Miguel-Hidalgo, J.J., Cacabelos, R. Hippocampal neurodegeneration: animal models for Alzheimer’s disease. Ann. Psychiat., 6:147-157 (1996).
  • Álvarez, X.A., Miguel-Hidalgo, J.J., Fernández-Novoa, L., Beyer, K., Lao, J.I., Vecino, B., Cacabelos, R. Behavioral deficits in rats with hippocampal neurodegeneration induced by - amyloid implants. Ann. Psychiat., 6:159-171 (1996).
  • Beyer, K., Lao, J.I., Cacabelos, R. Molecular genetics and genotyping in Alzheimer’s disease. Ann. Psychiat., 6:173-187 (1996).
  • Cacabelos, R., Rodríguez, B., Carrera, C., Beyer, K., Lao, J.I., Sellers, M.A. APOE-related dementia symptoms: Frequency and progression. Ann. Psyciat., 6:189-205 (1996).
  • Lao, J.I., Beyer, K., Cacabelos, R. Genetic markers of mental retardation. Ann. Psychiat., 6:207-217 (1996).
  • Maneiro, E., Lombardi, V.R.M., Cacabelos, R. Cytotoxic effects of beta amyloid, histamine, LPS and serum from Alzheimer’s disease patients on cultured endothelial cells. A preliminary study. Ann. Psychiat., 6:231-239 (1996).
  • Lombardi, V.R.M., Maneiro, E., Cacabelos, R. Neurologic manifestations linked to AIDS and HIV-l infection. Ann. Psychiat., 6:309-330 (1996).
  • Maneiro, E., Lombardi, V.R.M., Cacabelos, R. Rat cell cultures: Experimental models to study neurodegenerative disorders and new pharmacological compounds. Ann. Psychiat., 6:331-365 (1996).
  • Beyer, K., Lao, J.I., Álvarez, X.A., Cacabelos, R. Different implications of APOE-4 in Alzheimer’s disease and vascular dementia in the Spanish population. Alzheimer’s Res., 2:215-220 (1996).
  • Álvarez, X.A., Franco, A., Fernández-Novoa, L., Cacabelos, R. Blood levels of histamine, IL-l, and TNF- in patients with mild to moderate Alzheimer disease. Mol. Chem. Neuropathol., 29:237-252 (1996).
  • Cacabelos, R., Rodríguez, B., Carrera, C., Caamaño, J., Beyer, K., Lao, J.I., Sellers, M.A. APOE-Related frequency of cognitive and noncognitive symptoms in dementia. Meth. Find. Exp. Clin. Pharmacol., 18:693-706 (1996).
  • Lombardi, V.R.M., Maneiro, E., Cacabelos, R. Central nervous system damage during HIV infection. Meth. Find. Exp. Clin. Pharmacol., 18:707-722 (1996).
  • Cacabelos, R., Caamaño, J., Vinagre, D., Lao, J.I., Beyer, K., Álvarez, X.A. Brain mapping and transcranial Doppler ultrasonography in Alzheimer’s disease drug monitoring. In: Alzheimer disease: From Molecular Biology to Therapy. R. Becker, E. Giacobini (Eds.). Birkhäuser, Boston, pp. 469-473 (1996).
  • Álvarez, X.A., Zas, R., Lagares, R., Fernández-Novoa, L., Franco-Maside, A., Miguel-Hidalgo, J.J., Cacabelos, R. Anapsos: New therapeutic strategies for neurodegeneration and brain aging with neuroimmunotrophic factors. In: Alzheimer disease: From Molecular Biology to Therapy. R. Becker, E. Giacobini (Eds.). Birkhäuser, Boston, pp. 367-372 (1996).
  • Fernández-Novoa, L., Franco-Maside, A., Álvarez, X.A., Cacabelos, R. Effects of histamine and alpha-fluoromethylhistidine on brain tumor necrosis factor levels in rats. Immun. Res., 44:55-57 (1995).
  • Cacabelos, R. From loyalty to efficacy. Ann. Psychiat., 5:1-111 (1995).
  • Takeda, M., Cacabelos, R. Professor Nishimura and his work: Summary of a life devoted to Psychiatry. Ann. Psychiat., 5:1-13 (1995).
  • Gómez, M.J., Caamaño, J., Vinagre, D., Franco-Maside, A., Álvarez, X.A., Fernández-Novoa, L., Zas, R., Novo, R., Cacabelos, R. Non-cognitive impairment in senile dementia: A neuropsychological study. Ann. Psychiat., 5:31-40 (1995).
  • Kudo, T., Takeda, M., Cacabelos, R., Nishimura, T. Biomarkers for Alzheimer’s disease in cerebrovascular fluids. Ann. Psychiat., 5:41-52 (1995).
  • Nakamura, Y., Cacabelos, R., Takeda, M. Impairment of axonal transport in Alzheimer’s disease. Ann. Psychiat., 5:53-64 (1995).
  • Fernández-Novoa, L., Cacabelos, R. The histaminergic system in Alzheimer’s disease. Ann. Psychiat., 5:127-158 (1995).
  • Caamaño, J., Vinagre, D., Gómez, M.J., Novo, B., Zas, R., Franco, A., Cacabelos, R. Schizophrenic patients show lower peripheral resistances in the middle cerebral artery territory than healthy subjects: A preliminary transcranial Doppler study. Ann. Psychiat., 5:159-166 (1995).
  • Álvarez, X.A., Zas, R., Lagares, R., Franco, A., Beyer, K., Polo, E., García, M., Guez, D., Fernández-Novoa, L., Cacabelos, R. Effects of S9977-2, a new cognition-enhancing drug, on behavior and brain neurotransmitters in rats. Ann. Psychiat., 5:247-265 (1995).
  • Álvarez, X.A., Zas, R., Lagares, R., Franco, A., Maneiro, E., Miguel-Hidalgo, J.J., Lao, J.I., Fernández-Novoa, L., Díaz, J., Cacabelos, R. Neuroimmunomodulatory and neurotrophic activity of Anapsos: Studies with laboratory animals. Ann. Psychiat., 5:267-280 (1995).
  • Franco-Maside, A., Vinagre, D., Caamaño, J., Gómez, M.J., Álvarez, X.A., Fernández-Novoa, L., Zas, R., Novo, B., Polo, E., García, M., Castagné, I., Newman, E., Guez, D., Cacabelos, R. Effects of S12024 on brain electrical activity parameters in patients with Alzheimer’s disease. Ann. Psychiat., 5:281-294 (1995).
  • Cacabelos, R., Caamaño, J., Gómez, M.J., Fernández-Novoa, L., Franco-Maside, A., Vinagre, D., Novo, B., Zas, R., Álvarez, X.A. Treatment of Alzheimer’s disease with CDP-choline: Effects on mental performance, brain electrical activity, cerebrovascular parameters and cytokine production. Ann. Psychiat., 5:295-315 (1995).
  • Cacabelos, R. The multidisciplinary path to brain aging research and healthy environment for the elderly. Neurogerontol. Neurogeriat., 1:ix-x (1995).
  • Cacabelos, R., Frey, H., Nishimura, T., Takeda, M., Winblad, B. Introduction to neurogerontology and psychogeriatrics. Neurogerontol. Neurogeriat., 1:1-4 (1994).
  • Cacabelos, R. The aging process and theories of aging: Implications for neurogerontology. Neurogerontol. Neurogeriat., 1:5-20 (1995).
  • Álvarez, X.A., Lagares, R., Zas, R., Fernández-Novoa, L., Beyer, K., Maneiro, E., Franco-Maside, A., Lao, J.I., Miguel-Hidalgo, J.J., Cacabelos, R. Geriatric psychoneuroendocrinology. Neurogerontol. Neurogeriat., 1:61-83 (1995).
  • Gómez, M.J., Caamaño, J., Vinagre, D., Franco, A., Cacabelos, R. Cognitive and non-cognitive profiles in cerebrovascular disorders and senile dementia: A neuropsychological study. Neurogerontol. Neurogeriat., 1:107-118 (1995).
  • Franco-Maside, A., Vinagre, D., Caamaño, J., Álvarez, X.A., Fernández-Novoa, L., Novo, B., Zas, R., Gómez, M.J., Cacabelos, R. Brain mapping in neurogeriatrics. Neurogerontol. Neurogeriat., 1:119-139 (1995).
  • Caamaño, J., Gómez, M.J., Vinagre, D., Franco, A., Fernández-Novoa, L., Álvarez, X.A., Novo, B., Zas, R., Cacabelos, R. Transcranial Doppler ultrasonography in neurogeriatric disorders. Neurogerontol. Neurogeriat., 1:141-157 (1995).
  • Cacabelos, R. Alzheimer’s disease: Etiopathogenic factors. Neurogerontol. Neurogeriat., 1:299-328 (1995).
  • Cacabelos, R., Caamaño, J., Álvarez, X.A., Gómez, M.J., Franco-Maside, A., Vinagre, D., Fernández-Novoa, L., Lao, J.I., Beyer, K., Recuero, M., Sastre, I., Bellido, M.J., Valdivieso, F., Vigo-Pelfrey, C. Diagnostic criteria and genotyping in Alzheimer’s disease. Neurogerontol. Neurogeriat., 1:329-353 (1995).
  • Caamaño, J., Gómez, M.J., Vinagre, D., Franco, A., Fernández-Novoa, L., Álvarez, X.A., Novo, B., Zas, R., Cacabelos, R. Transcranial Doppler ultrasonography in neurogeriatric disorders. Meth. Find. Exp. Clin. Pharmacol., 17:135-148 (1995).
  • Cacabelos, R. Tacrina: Primera generación de fármacos antidemencia. Med. Clin., 105:105-115 (1995).
  • Cacabelos, R. Enfermedad de Alzheimer. Parte I. Epidemiología y Etiopatogenia. FOMECO, 3:212-220 (1995).
  • Cacabelos, R. Enfermedad de Alzheimer. Parte II. Diagnóstico y tratamiento. FOMECO, 3:268-281 (1995).
  • Franco-Maside, A., Vinagre, D., Caamaño, J., Álvarez, X.A., Fernández-Novoa, L., Novo, B., Zas, R., Gómez, M.J., Cacabelos, R. Brain electrical activity in neurogerontology and psychogeriatric disorders. Meth. Find. Exp. Clin. Pharmacol., 17:207-224 (1995).
  • Cacabelos, R., Álvarez, X.A., Franco-Maside, A., Fernández-Novoa, L., Caamaño, J. Serum tumor necrosis factor (TNF) in Alzheimer’s disease and multi-infarct dementia. Meth. Find. Exp. Clin. Pharmacol., 16:29-35 (1994).
  • Cacabelos, R. Enfermedad de Alzheimer: Disfunción neuroinmune y nuevas formas de intervención terapéutica. Med. Clin., 102:420-422 (1994).
  • Cacabelos, R., Álvarez, X.A., Fernández-Novoa, L., Franco, A., Mangues, R., Pellicer, A., Nishimura, T. Brain interleukin-1 in Alzheimer’s disease and vascular dementia. Meth. Find. Exp. Clin. Pharmacol., 16:141-151 (1994).
  • Caamaño, J., Gómez, M.J., Franco, A., Cacabelos, R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer’s disease. Meth. Find. Exp. Clin. Pharmacol., 16:211-218 (1994).
  • Fernández-Novoa, L., Álvarez, X.A., Franco-Maside, A., Caamaño, J., Cacabelos, R. CDP-choline-induced blood histamine changes in Alzheimer’s disease. Meth. Find. Exp. Clin. Pharmacol., 16:279-284 (1994).
  • Álvarez, X.A., Franco, A., Fernández-Novoa, L., Cacabelos, R. Effects of neurotoxic lesions in histaminergic neurons on brain tumor necrosis factor levels. Agents Actions, 41:C70-C72 (1994).
  • Vinagre, D., Franco-Maside, A., Gómez, M.J., Caamaño, J., Cacabelos, R. Brain electrical activity mapping in cerebrovascular disorders and senile dementia. Drugs Today, 30:275-281 (1994).
  • Caamaño, J., Gómez, M.J., Vinagre, D., Franco-Maside, A., Cacabelos, R. Transcranial Doppler ultrasonography in senile dementia. Drugs Today, 30:283-293 (1994).
  • Cacabelos, R., Nordberg, A., Caamaño, J., Franco-Maside, A., Fernández-Novoa, L., Gómez, M.J., Álvarez, X.A., Takeda, M., Prous, J. Jr. Nishimura, T., Winblad, B. Molecular strategies for the first generations of anti-dementia drugs (I): Tacrine and related compounds. Drugs Today, 30:295-337 (1994)
  • Cacabelos, R., Winblad, B. Alzheimer’s disease in a changing world. Ann. Psychiatry, 4:V-VI (1994).
  • Gómez, M.J., Caamaño, J., Cacabelos, R. Alzheimer’s disease assessment scale in senile dementia and in geriatric patients without cognitive impairment. Ann. Psychiatry, 4:69-81 (1994).
  • Vinagre, D., Franco-Maside, A., Gómez, M.J., Caamaño, J., Cacabelos, R. Brain electrical activity mapping in cerebrovascular disorders and senile dementia. Ann. Psychiatry, 4:195-204 (1994).
  • Caamaño, J., Gómez, M.J., Vinagre, D., Franco, A., Cacabelos, R. Transcranial Doppler ultrasonography in senile dementia. Ann. Psychiatry, 4:205-219 (1994).
  • Cacabelos, R., Nordberg, A., Caamaño, J., Franco-Maside, A., Fernández-Novoa, L., Gómez, M.J., Álvarez, X.A., Takeda, M., Prous, J., Nishimura, T., Winblad, B. Therapeutic strategies in Alzheimer’s disease. Ann. Psychiatry, 4:221-279 (1994).
  • Cacabelos, R., Caamaño, J., Álvarez, X.A., Fernández-Novoa, L., Franco, A. Enfermedad de Alzheimer. Bases moleculares, criterios diagnósticos y normativa terapéutica. JANO Med. Hum., 1103:39-64 (1994).
  • Cacabelos, R., Takeda, M., Nishimura, T. Tratamiento psicofarmacológico convencional para control de trastornos psiquiátricos asociados a la enfermedad de Alzheimer. JANO Med. Hum., 1103:67-79 (1994).
  • Cacabelos, R., Álvarez, X.A., Caamaño, J., Franco, A., Fernández-Novoa, L., Gómez, M.J., Novo, B., Zas, R. Primeras generaciones de fármacos anti-demencia. JANO Med. Hum., 1104:25-59 (1994).
  • Cacabelos, R., Caamaño, J., Franco, A., Fernández-Novoa, L., Álvarez, X.A. Agentes nootrópicos y fármacos polivalentes. JANO Med. Hum., 1105:25-55 (1994).
  • Franco-Maside, A., Caamaño, J., Gómez, M.J., Cacabelos, R. Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer’s disease. Meth. Find. Exp. Clin. Pharmacol., 16:597-607 (1994).
  • Álvarez, X.A., Franco, A., Fernández-Novoa, L., Cacabelos, R. Effects of neurotoxic lesions in the posterior hypothalamic region on psychomotor activity and learning. Agents Actions, 43:21-23 (1994).
  • Cacabelos, R. Enfermedad de Alzheimer; Bases etiopatogénicas para nuevas estrategias terapéuticas. Clínica, 7:31-53 (1994)

 

  • Cacabelos, R. Marcadores genéticos en trastornos neuropsiquiátricos: cartografía genética y prospecciones diagnósticas y terapéuticas (II). Med. Clin., 100:28-36 (1993).
  • Caamaño, J., Gómez, M.J., Cacabelos, R. Transcranial Doppler ultrasonography in senile dementia: Neuropsychological correlates. Meth. Find. Exp. Clin. Pharmacol., 15:193-199 (1993).
  • Cacabelos, R., Álvarez, X.A., Franco, A., Fernández-Novoa, L. Dose- and time-dependent effects of histamine on hypothalamic levels of interleukin-1 in rats. Agents Actions, 38:C260- C262 (1993).
  • Cacabelos, R., Hofman, A., Mullan, M., Ferris, S.M., Portera, A., Frey, H., Swaab, D F., de Leon, M., Terry, R., Masters, C.L., Iqbal, K., Wisniewski, H.M., Takeda, M., Giacobini, E., Nordberg, A., Winbald, B. Alzheimer’s disease: Scientific progress for future trends. Drug News Perspect., 6:242-244 (1993).
  • Álvarez, X.A., Cacabelos, R. Influence of growth hormone (GH) and GH-releasing factor on locomotor activity in rats. Peptides, 14:707-712 (1993).
  • Cacabelos, R., Álvarez, X.A., Franco-Maside, A., Fernández-Novoa, L., Caamaño, J. Effect of CDP-choline on cognition and immune function in Alzheimer’s disease and multi-infarct dementia. Ann. New York Acad. Sci., 695:321-323 (1993).
  • Niimi, M., Mochizuki, T., Cacabelos, R., Yamatodani, A. Increase of histidine decarboxylase activity in mice hypothalamus after intracerebroventricular administration of lipopolysaccharide. Meth. Find. Exp. Clin. Pharmacol., 15:509-514 (1993).
  • Álvarez, X.A., Franco, A., Fernández-Novoa, L., Cacabelos, R. Effects of S 9977-2 on psychomotor activity, learning and brain interleukin-1 levels in rats. Meth. Find. Exp. Clin. Pharmacol., 15:587-595 (1993).
  • Fernández-Novoa, L., Álvarez, X.A., Franco, A., Caamaño, J., Cacabelos, R. Histamine-induced interleukin-1 changes in the rat hypothalamus. Meth. Find. Exp. Clin. Pharmacol., 15:735-741 (1993).
  • Álvarez, X.A., Franco, A., Cacabelos, R. Psiconeuroendocrinología geriátrica. Endocrinología, 39:135-145 (1992).
  • Cacabelos, R., Niigawa, H., Yamatodani, A., Fukui, H., Nishimura, T., Wada, H. Vasopressin-induced changes in brain histamine and H-1 receptors. Exp. Clin. Endocrinol. (Life Sci. Adv.), 11:37-44 (1992).
  • Cacabelos, R. Neuropéptidos en psiquiatría (I). Monogr. Psiquiatría, 3:7-9 (1992).
  • Franco, A., Álvarez, X.A., Cacabelos, R. Acciones centrales de los neuropéptidos. Monogr. Psiquiatría, 3:10-18 (1992).
  • Álvarez, X.A., Franco, A., Cacabelos, R. Neuropéptidos y envejecimiento. Monogr. Psiquiatría, 3:19-28 (1992).
  • Cacabelos, R. Alteraciones neuropeptidérgicas en trastornos mentales. Monogr. Psiquiatría, 4:3-12 (1992).
  • Cacabelos, R. Disfunción neuropeptidérgica en la enfermedad de Alzheimer. Monogr. Psiquiatría, 4:13-21 (1992).
  • Cacabelos, R. Factores neurotróficos: Neurobiología molecular y alteraciones en trastornos del sistema nervioso. Monogr. Psiquiatría, 4:22-28 (1992).
  • Cacabelos, R. Marcadores genéticos en trastornos neuropsiquiátricos: Mapeo genético y prospecciones diagnósticas y terapéuticas. Med. Clin., 99:505-514 (1992).
  • Cacabelos, R. Alzheimer’s disease: News and prospects. Drug News Perspect., 5:501-506 (1992).
  • Cacabelos, R. Prof. Hiroshi Wada or the art of teamwork. Ann. Psychiat., 3:V-VI (1992).
  • Cacabelos, R., Fernández-Novoa, L., Franco-Maside, A., Álvarez, X.A. Neuroimmune function of brain histamine: implications for neurotrophic activity and neurotoxicity. Ann. Psychiat., 3:147-200 (1992).
  • Cacabelos, R., Álvarez, X.A., Franco, A., Fernández-Novoa, L., Caamaño, J., Valle-Inclán, F. Therapeutic effects of CDP-choline in Alzheimer’s disease and multi-infarct dementia: psychometric assessment and immune function. Ann. Psychiat., 3:233-245 (1992).
  • Caamaño, J., Valle-Inclán, F., Cacabelos, R. Middle cerebral artery blood flow velocity in patients with vascular dementia: assessment by transcranial Doppler ultrasonography. Ann. Psychiat., 3:273-280 (1992).
  • Álvarez, X.A., Cacabelos, R. Psychoneuroendocrinology and the aging brain. Ann. Psychiat., 3:281-299 (1992).
  • Álvarez, X.A., Franco, A., Fernández-Novoa, L., Cacabelos, R. Effects of anapsos on behavior and brain cytokines in rats. Ann. Psychiat., 3:329-341 (1992).
  • Cacabelos, R., Fernández-Novoa, L., Pérez-Trullén, J.M., Franco-Maside, A., Álvarez, X.A. Serum histamine in Alzheimer’s disease and multi-infarct dementia. Meth. Find. Exp. Clin. Pharmacol., 14:711-715 (1992).
  • Cacabelos, R., Álvarez, X.A. Histidine decarboxylase inhibition induced by alpha-fluoromethylhistidine provokes learning-related hypokinetic activity. Agents Actions, 33:131-134 (1991).
  • Cacabelos, R. Demencia senil: Estrategias para una década. Rev. Clin. Esp., 189:51-53 (1991).
  • Cacabelos, R., Barquero, M., García, P., Álvarez, X.A., Varela de Seijas, E. Cerebrospinal fluid interleukin-1 (IL-1) in Alzheimer’s disease and neurological disorders. Meth. Find. Exp. Clin. Pharmacol., 13:455-458 (1991).
  • Cacabelos, R., Franco-Maside, A., Álvarez, X.A. Interleukin-l in Alzheimer’s disease and multi-infarct dementia: Neuropsychological correlations. Meth. Find. Exp. Clin. Pharmacol., 13:703-708 (1991).
  • Pérez-Trullén, J.M., Vázquez-André, M.C., Cacabelos, R. Los potenciales evocados en la enfermedad de Alzheimer. La onda P300. Anuario Psiquiátrico, 2:77-97 (1991).
  • Cacabelos, R. Función neuroinmune en trastornos mentales. Anuario Psiquiátrico, 2:135-154 (1991).
  • Álvarez, X.A., Franco, A., Cacabelos, R. Efectos de la somatotropina biosintética (r-hGH) y la somatoliberina [GRF(1-29)NH2] sobre la actividad psicomotriz. Anuario Psiquiátrico, 2:189-199 (1991).
  • Cacabelos, R. Alteraciones neuroquímicas en la enfermedad de Alzheimer: Neurotransmisores clásicos, sistemas enzimáticos y factores de membrana. Geriatrika, X:39-53 (1991).
  • Álvarez, X.A., Cacabelos, R. Age- and sex-related serum growth hormone (GH) levels in psychiatric patients and healthy control subjects. A correlation study between GH values and cognitive performance. Exp. Clin. Endocrinol. (Life Sci. Adv.), 10:245-257 (1991).
  • Martín-Loeches, M., Gil, P., Jiménez, F., Expósito, F.J., Miguel, F., Cacabelos, R., Rubia, F.J. Topographic maps of brain electrical activity in primary degenerative dementia of the Alzheimer type and multiinfarct dementia. Biol. Psychiatry, 29:211-223 (1991).

Libros, monografía y capítulos

  • Cacabelos R, Carril JC, Teijido O. Chapter 5. Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development. In : Vaiserman AM (Ed). Anti-aging Drugs: From Basic Research to Clinical Practice 2017; 75-141. DOI:10.1039/9781782626602-00075.
  • Cacabelos R, Teijido O. 2017. Epigenetic Drug Discovery for Alzheimer’s Disease. In: Moskalev & Vaiserman Editors (1st Edition). Handbook of models on human aging. Elsevier, Inc., USA. [In Press]
  • Cacabelos R, Teijido O. 2017. Epigenetics of Brain Aging. Chapter 46. In: Michael Conn Editor (Vol 2). Handbook of Models for Human Aging (2nd Edition). Elsevier, San Diego, USA. [In Press]
  • Cacabelos R, Torrellas C, López-Muñoz F. Pharmacogenomics of antidepressants drugs. In: Srinivasa V (ed). Melatonin, Neuroprotective Agents and Antidepressant Therapy. Springer-India. 2016; dOI 10.1007/978-81-322-2803-5_35.
  • Cacabelos R, Torrellas C, López-Muñoz F. Pharmacogenomics of antidepressants drugs. In: Srinivasa V (ed). Melatonin, Neuroprotective Agents and Antidepressant Therapy. Springer-India. 2016; DOI 10.1007/978-81-322-2803-5_35.
  • Cacabelos R, Torrellas C. Pharmacoepigenomics. In: Medical Epigenetics. T. Tollefsbol (Ed). Elsevier-AP, Amsterdam http://dx.doi.org/10.1016/B978-0-12-803239-8.00032-6.
  • Cacabelos R (Ed). Research Reports 2006-2010. Vol. 4. EuroEspes Publishing Co., Coruña (2015).
  • Cacabelos R (Ed). Research Reports 2011-2014. Vol. 5. EuroEspes Publishing Co., Coruña (2015).
  • Cacabelos R (Ed). Camilo José Cela University Health Science Reports 2013. CJC University Press, Madrid (2015).
  • Cacabelos R (Ed). Camilo José Cela University Health Science Reports 2014. CJC University Press, Madrid (2015).
  • Cacabelos R. The first version of the EuroEspes Pharmacogenetic Card. In: Cacabelos R (Ed). Research Reports 2006-2010. Vol. 4, pp. 1-2, EuroEspes Publishing Co., Coruña (2015).
  • Cacabelos R. The First Guide of PharmacoGenomics, the EuroPharmaGenics (EPG) Database, and the first Chair of Genomic Medicine in Spain. In: Cacabelos R (Ed). Research Reports 2011-2014. Vol. 5, pp. 1-2. EuroEspes Publishing Co., Coruña (2015).
  • Cacabelos R. Designing the future. In: Cacabelos R (Ed). Camilo José Cela University Health Science Reports 2013; pp. 1-2, CJC University Press, Madrid (2015).
  • Cacabelos R. Quality vs Quantity. Scientific Development to serve public welfare. In: Cacabelos R (Ed). Camilo José Cela University Health Science Reports 2014, pp. 1-2, CJC University Press, Madrid (2015).
  • Cacabelos R, Torrellas C, Cacabelos P, Villanueva MJ, Piñeiro S, Solveira. Pharmacogenetics of neurodegenerative disorders. In: Preventive and Predictive Genetics: Towards Personalized Medicine. Grech & Grossman Eds. Springer, 2015:173-240.
  • Cacabelos R, Torrellas C, Tellado I, Cacabelos P, López-Muñoz F. Genomics, therapeutics and Pharmacogenomics of attention-deficit/hyperactivity disorder. In: Attention Deficit Hyperactivity Disorder (ADHD). López-Muñoz F, Álamo C (Eds). Nova Science Publishers, 2015:65-256.
  • Cacabelos, R., Cacabelos, P., Torrellas, C. Personalized Medicine of Alzheimer’s Disease. In: Handbook of Pharmacogenomics and Stratified Medicine. Padmanabhan, S. (Ed.). Elsevier, UK, pp. 563-615 (2014).
  • Aliev, A., Horecky, J., Vancova, O., Ashraf, G.M., Hassan, I., Bragin, V., Bragin, I., Shevtsova, E., Klochkov, S.G., Kosenko, E.A., Cacabelos, R., Bachurin, S.O., Benberin, V.V., Kaminsky, Y.G.
  • The three-vessel occlusion as a model of vascular dementia – Oxidative stress and mitochondrial failure as an indicator of brain hypoperfusion. In: Systems Biology of Free Radicals and Antioxidants. Laher, I. (Ed.). Springer-Verlag Berlin Heidelberg, Germany. pp. 2023-32 (2014).
  • Aliev, G., Ashraf, G.M., Horecky, J., Vancova, O., Gvozdjakova, A., Kucharska, J, Palacios, H.H., Li, Y.,
  • Perveen, A., Khan, T.A., Bragin, V., Bragin, I., Shevtsova, E., Klochkov, S.G., Kosenko, E.A., Cacabelos, R., Kaminsky, Y.G., Sudakov, K.V., Benberin, V.V., Bachurin, S.O. Potential preventive effects of coenzyme Q and creatine supplementation on brain energy metabolism in rats exposed to chronic cerebral hypoperfusion. In: Systems Biology of Free Radicals and Antioxidants. Laher, I. (Ed.). Springer-Verlag Berlin Heidelberg, Germany. pp. 2033-48 (2014).
  • Aliev, G., Li, Y., Palacios, H.H., Obrenovich, M.E., Bragin, V., Bragin, I., Shevtsova, E., Klochkov, S.G., Kosenko, E.A., Cacabelos, R., Kaminsky Y.G., Bachurin, S.O., Benberin, V.V. Oxidative stress-induced mitochondrial damage as a hallmark for drug development in the context of the neurodegeneration, cardiovascular, and cerebrovascular diseases. In: Systems Biology of Free Radicals and Antioxidants. Laher, I. (Ed.). Springer-Verlag Berlin Heidelberg, Germany. pp. 2083-126 (2014).
  • Aliev, G., Li, Y., Palacios, H.H., Obrenovich, M.E., Bragin, V., Bragin, I., Shevtsova, E., Klochkov, S.G., Kosenko, E.A., Kaminsky, Y.G., Bachurin, S.O., Cacabelos R. Atherosclerotic lesions and mitochondrial DNA deletions as a primary hallmark of the brain microcirculation – Implication in the pathogenesis of Alzheimer’s disease. In: Systems Biology of Free Radicals and Antioxidants. Laher, I. (Ed.). Springer-Verlag Berlin Heidelberg, Germany. pp. 2127-145 (2014).
  • Aliev, G., Burzynski, G., Ashraf, G.M., Jabir, N.R., Cacabelos, R., Benberin, V.V., Burzynski, S.R. Implication of oxidative stress-induced oncogenic signaling pathways as a treatment strategy for neurodegeneration and cancer. In: Systems Biology of Free Radicals and Antioxidants. Laher, I. (Ed.). Springer-Verlag Berlin Heidelberg, Germany. pp. 2325-47 (2014).
  • Cacabelos, R. Scientific leadership and mental health service to the community. In: A 120-year history of growth and development. Takeda, M. (Ed). Department of Psychiatry Osaka University Medical School, Osaka. pp. 253-8 (2014).
  • Cacabelos, R (Ed). World Guide for Drug Use and Pharmacogenomics. EuroEspes Publishing, Coruña (2012).
  • Cacabelos R (Ed). Preface. The Path to Pharmacogenomics. In: World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012: v-vi.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. A2M (alpha-2-macroglobulin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:811-812.
  • Cacabelos R, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. ABCA1 (ATP-binding cassette, sub-family A (ABC1), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:812-824.
  • Cacabelos R, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. ABCB1 (ATP-binding cassette, sub-family B (MDR/TAP), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:824-928.
  • Cacabelos R, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCB11 (ATP-binding cassette, sub-family B (MDR/TAP), member 11). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:928-930.
  • Cacabelos R, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC1 (ATP-binding cassette, sub-family C (CFTR/MRP), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:930-944.
  • Cacabelos R, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC2 (ATP-binding cassette, sub-family C (CFTR/MRP), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:944-962.
  • Cacabelos R, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC3 (ATP-binding cassette, sub-family C (CFTR/MRP), member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:963-965.
  • Cacabelos R, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC4 (ATP-binding cassette, sub-family C (CFTR/MRP), member 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:965-971.
  • Cacabelos R, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC6 (ATP-binding cassette, sub-family C (CFTR/MRP), member 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:971-979.
  • Cacabelos R, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCC8 (ATP-binding cassette, sub-family C (CFTR/MRP), member 8). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:979-985.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCG1 (ATP-binding cassette, sub-family G (WHITE), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:985-996.
  • Cacabelos R, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A. ABCG2 (ATP-binding cassette, sub-family G (WHITE), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:996-1024.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ABL1 (c-abl oncogene 1, non-receptor tyrosine kinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1025-1026.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACACA (acetyl-coA carboxylase alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1026-1027.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACE (angiotensin I converting enzyme (peptidyl-dipeptidase A) 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1027-1034.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACE2 (angiotensin I converting enzyme (peptidyl-dipeptidase A) 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1034-1036.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACHE (acetylcholinesterase (Yt blood group)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1036-1041.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACOX1 (acyl-CoA oxidase 1, palmitoyl). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1041-1042.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL1 (acyl-CoA synthetase long-chain family member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1042-1043.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL3 (acyl-CoA synthetase long-chain family member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1043-1044.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL4 (acyl-CoA synthetase long-chain family member 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1044-1045.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL5 (acyl-CoA synthetase long-chain family member 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1045-1046.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACSL6 (acyl-CoA synthetase long-chain family member 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1046.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ACVRL1 (activin A receptor type II-like 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1046-1047.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADA (adenosine deaminase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1047-1049.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADCY9 (adenylate cyclase 9). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1049-1050.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADD1 (adducin 1 (alpha)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1050-1052.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADH1A (alcohol dehydrogenase 1A (class 1), alpha polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1052-1053.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADH1B (alcohol dehydrogenase 1B (class 1), beta polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1053-1054.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADH1C (alcohol dehydrogenase 1C (class 1), gamma polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1054-1056.
  • Lombardi V, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADIPOQ (adiponectin, C1Q and collagen domain containing). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1056-1060.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADORA2A (adenosine A2a receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1060-1062.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRA1A (adrenergic, alpha-1A-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1062-1064.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRA2A (adrenergic, alpha-2A-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1064-1067.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRA2C (adrenergic, alpha-2C-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1067-1069.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRB1 (adrenergic, beta-1-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1069-1073.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRB2 (adrenergic, beta-2-, receptor, surface). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1073-1080.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ADRB3 (adrenergic, beta-3-, receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1080-1082.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AGPAT2 (1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acetyltransferase, beta)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1082-1083.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AGT (angiotensinogen (serpin peptidase inhibitor, clade A, member 8)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1083-1088.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AGTR1 (angiotensin II receptor, type 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1088-1092.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AGXT (alanine-glyoxylate aminotransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1092-1093.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AHR (aryl hydrocarbon receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1093-1098.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AKR1C4 (aldo-keto reductase family 1, member C4 (chlordecone reductase; 3-alpha hydroxysteroid dehydrogenase, type I; dihydrodiol dehydrogenase 4)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1098-1099.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALAD (aminolevulinate dehydratase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1099-1100.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALDH1A1 (aldehyde dehydrogenase 1 family, member A1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1100-1103.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALDH2 (aldehyde dehydrogenase 2 family (mitochondrial)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1103-1106.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALDH3A1 (aldehyde dehydrogenase 3 family, member A1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1106-1108.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ALOX5 (arachidonate 5-lipoxygenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1108-1111.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AOX1 (aldehyde oxidase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1111.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APC (adenomatous polyposis coli). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1112-1115.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOA1 (apolipoprotein A-I). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1115-1116.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOA5 (apolipoprotein A-V). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1116-1118.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOB (apolipoprotein B (including Ag(x) antigen)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1118-1119.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOC3 (apolipoprotein C-III). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1119-1120.
  • Carril JC, Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. APOD (apolipoprotein D). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1120-1121.
  • Cacabelos R, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. APOE (apolipoprotein E). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1121-1161.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Lombardi V, Takeda M, Cacabelos R. APP (amyloid beta (A4) precursor protein). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1161-1183.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AR (androgen receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1183-1189.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ARG1 (arginase, liver). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1189-1190.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. AS3MT (arsenic (+3 oxidation state) methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1190-1191.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1191-1192.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ATP7A (ATPase, Cu2+ transporting, alpha polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1192-1193.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BCAR1 (breast cancer anti-estrogen resistance 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1194.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BCHE (butyrylcholinesterase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1194-1196.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BCR (breakpoint cluster region). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1196-1197.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BDKRB2 (bradykinin receptor B2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1197.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BDNF (brain-derived neurotrophic factor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1198-1200.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BLK (B lymphoid tyrosine kinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1200-1201.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BLMH (bleomycin hydrolase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1201-1202.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BMPR2 (bone morphogenetic protein receptor, type II (serine/threonine kinase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1202-1203.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BRAF (v-raf murine sarcoma viral oncogene homolog B1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1203-1204.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BRCA1 (breast cancer 1, early onset). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1204-1208.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. BRCA2 (breast cancer 2, early onset). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1208-1209.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CACNG2 (calcium channel, voltage-dependent, gamma subunit 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1210.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CALU (calumenin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1210-1211.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CASR (calcium-sensing receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1211-1212.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CAT (catalase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1212-1217.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CBR1 (carbonyl reductase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1217-1218.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CBR3 (carbonyl reductase 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1218-1219.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CBS (cystathionine beta-synthase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1219-1220.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CCND1 (cyclin D1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1220-1223.
  • Lombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CCR5 (chemokine (C-C motif) receptor 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1223-1229.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDA (cytidine deaminase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1229.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDK1 (cyclin-dependent kinase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1229-1232.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDK2 (cyclin-dependent kinase 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1232-1234.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDK4 (cyclin-dependent kinase 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1234-1236.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDK6 (cyclin-dependent kinase 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1236-1238.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CDKN2A (cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1238-1241.
  • Lombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CES1 (carboxylesterase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1241-1242.
  • Lombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CES2 (carboxylesterase 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1242-1243.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CETP (cholesteryl ester transfer protein, plasma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1243-1244.
  • Lombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CFH (complement factor H). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1244-1245.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CFTR (cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1245-1248.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHAT (choline O-acetyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1248-1249.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHDH (choline dehydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1249.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRM1 (cholinergic receptor, muscarinic 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1249-1250.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRM2 (cholinergic receptor, muscarinic 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1250-1251.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRM3 (cholinergic receptor, muscarinic 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1251-1252.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRNA1 (cholinergic receptor, nicotinic, alpha 1 (muscle)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1252.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRNA4 (cholinergic receptor, nicotinic, alpha 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1253-1254.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRNA5 (cholinergic receptor, nicotinic, alpha 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1254-1255.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHRNB2 (cholinergic receptor, nicotinic, beta 2 (neuronal)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1255-1256.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CHST3 (carbohydrate (chondroitin 6) sulfotransferase 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1256-1257.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CNR1 (cannabinoid receptor 1 (brain)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1257-1259.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. COL1A1 (collagen, type I, alpha 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1259-1262.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. COMT (catechol-O-methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1262-1264.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CREB1 (cAMP responsive element binding protein 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1264-1265.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CRHR1 (corticotropin releasing hormone receptor 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1265-1267.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CRHR2 (corticotropin releasing hormone receptor 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1267.
  • Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CRP (C-reactive protein, pentraxin-related). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1267-1270.
  • Lombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CSF1R (colony stimulating factor 1 receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1270-1272.
  • Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CSNK1E (casein kinase 1, epsilon). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1272-1273.
  • Lombardi V, Carrera I, Carril JC, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. CTLA4 (cytotoxic T-lymphocyte-associated protein 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1273-1274.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP1A1 (cytochrome P450, family 1, subfamily A, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1275-1297.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP1A2 (cytochrome P450, family 1, subfamily A, polypeptide 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1297-1334.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP1B1 (cytochrome P450, family 1, subfamily B, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1335-1347.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2A6 (cytochrome P450, family 2, subfamily A, polypeptide 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1347-1356.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2B6 (cytochrome P450, family 2, subfamily B, polypeptide 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1356-1368.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2C8 (cytochrome P450, family 2, subfamily C, polypeptide 8). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1368-1377.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1377-1401.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2C18 (cytochrome P450, family 2, subfamily C, polypeptide 18). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1401-1404.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1404-1423.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Tellado I, Takeda M. CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1423-1589.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2E1 (cytochrome P450, family 2, subfamily E, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1589-1613.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP2J2 (cytochrome P450, family 2, subfamily J, polypeptide 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1613-1622.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1622-1901.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Takeda M. CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1901-1902.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP4B1 (cytochrome P450, family 4, subfamily B, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1902-1906.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP4F2 (cytochrome P450, family 4, subfamily F, polypeptide 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1906-1911.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP7A1 (cytochrome P450, family 7, subfamily A, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1911-1932.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP11B2 (cytochrome P450, family 11, subfamily B, polypeptide 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1932-1943.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP19A1 (cytochrome P450, family 19, subfamily A, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1943-1979.
  • Cacabelos R, Fernández-Novoa L, Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A. CYP27A1 (cytochrome P450, family 27, subfamily A, polypeptide 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1979-1986.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DCK (deoxycytidine kinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1987-1988.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DDC (dopa decarboxylase (aromatic L-amino acid decarboxylase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1988-1989.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DHODH (dihydroorotate dehydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1989-1990.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DIO2 (deiodinase, iodothyronine, type II). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1990-1992.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DPP4 (dipeptidyl-peptidase 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1992-1993.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DPYD (dihydropyrimidine dehydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1993-1995.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DPYS (dihydropyrimidinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1995-1996.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD1 (dopamine receptor D1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1996-1998.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD2 (dopamine receptor D2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:1998-2002.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD3 (dopamine receptor D3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2002-2004.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD4 (dopamine receptor D4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2004-2006.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DRD5 (dopamine receptor D5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2006-2008.
  • Carrera I, Fernández-Novoa L, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. DTNBP1 (dystrobrevin binding protein 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2008-2010.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. EDN1 (endothelin 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2011-2013.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. EDNRA (endothelin receptor type A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2013-2015.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. EGFR (epidermal growth factor receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2015-2019.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. EPHX1 (epoxide hydrolase 1, microsomal (xenobiotic)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2020-2022.
  • Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERAP1 (endoplasmic reticulum aminopeptidase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2022-2023.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2023-2026.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERBB4 (v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2026-2028.
  • Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERCC1 (excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2028-2029.
  • Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERCC2 (excision repair cross-complementing rodent repair deficiency, complementation group 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2029-2032.
  • Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ERCC6 (excision repair cross-complementing rodent repair deficiency, complementation group 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2032-2034.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ESR1 (estrogen receptor 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2034-2042.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ESR2 (estrogen receptor 2 (ER beta)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2042-2046.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. F2 (coagulation factor II (thrombin)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2047-2049.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. F5 (coagulation factor V (proaccelerin, labile factor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2049-2050.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. F7 (coagulation factor VII (serum prothrombin conversion accelerator)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2050-2051.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FABP1 (fatty acid binding protein 1, liver). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2052-2053.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FABP2 (fatty acid binding protein 2, intestinal). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2053-2054.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FCER2 (Fc fragment of IgE, low affinity II, receptor for (CD23)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2054-2055.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FCGR2A (Fc fragment of IgG, low affinity IIa, receptor (CD32)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2055-2057.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FCGR3A (Fc fragment of IgG, low affinity IIIa, receptor (CD16a)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2057-2059.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FGB (fibrinogen beta chain). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2059-2061.
  • Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FKBP5 (FK506 binding protein 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2061-2062.
  • Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FLT3 (fms-related tyrosine kinase 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2062-2064.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FMO1 (flavin containing monooxygenase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2064-2066.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FMO2 (flavin containing monooxygenase 2 (non-functional)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2066-2067.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FMO3 (flavin containing monooxygenase 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2067-2068.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FMR1 (fragile X mental retardation 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2068-2069.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FOS (FBJ murine osteosarcoma viral oncogene homolog). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2069-2074.
  • Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. FSHR (follicle stimulating hormone receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2074-2075.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. G6PD (glucose-6-phosphate dehydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2076-2078.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GABRA6 (gamma-aminobutyric acid (GABA) A receptor, alpha 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2078-2079.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GCH1 (GTP cyclohydrolase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2079-2082.
  • Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GGCX (gamma-glutamyl carboxylase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2082-2083.
  • Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GGH (gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2083-2085.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GH1 (growth hormone 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2085-2086.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GHR (growth hormone receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2086-2088.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GNAS (GNAS complex locus). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2089-2091.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GNB3 (guanine nucleotide binding protein (G protein), beta polypeptide 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2091-2093.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRIA3 (glutamate receptor, ionotrophic, AMPA 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2093-2095.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRIK2 (glutamate receptor, ionotropic, kainate 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2095-2096.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRIK4 (glutamate receptor, ionotropic, kainate 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2096-2097.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRINA (glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2097.
  • Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRK5 (protein-coupled receptor kinase 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2097-2098.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GRM3 (glutamate receptor, metabotropic 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2098-2099.
  • Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSK3B (glycogen synthase kinase 3 beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2099-2101.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSS (glutathione synthetase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2102-2104.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTA1 (glutathione S-transferase alpha 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2104-2106.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTK1 (glutathione S-transferase kappa 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2106-2107.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTM1 (glutathione S-transferase mu 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2107-2111.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTO1 (glutathione S-transferase omega 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2111-2113.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTO2 (glutathione S-transferase omega 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2113.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTP1 (glutathione S-transferase pi 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2113-2118.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. GSTT1 (glutathione S-transferase theta 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2118-2121.
  • Carril JC, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HBB (hemoglobin, beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2122-2125.
  • Lombardi V, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HCP5 (HLA complex P5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2125-2126.
  • Carril JC, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HFE (hemochromatosis). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2126-2129.
  • Lombardi V, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-A (major histocompatibility complex, class I, A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2129-2131.
  • Lombardi V, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-B (major histocompatibility complex, class I, B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2131-2135.
  • Lombardi V, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-C (major histocompatibility complex, class I, C). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2135-2137.
  • Lombardi V, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-DPB1 (major histocompatibility complex, class II, DP beta 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2137-2139.
  • Lombardi V, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-DQA1 (major histocompatibility complex, class II, DQ alpha 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2139-2141.
  • Lombardi V, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HLA-DRB1 (major histocompatibility complex, class II, DR beta 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2141-2145.
  • Carril JC, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2145-2147.
  • Corzo L, Fernández-Novoa L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. HNF4A (hepatocyte nuclear factor 4, alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2147-2150.
  • Corzo L, Fernández-Novoa L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. HOXB13 (homeobox B13). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2150-2152.
  • Corzo L, Fernández-Novoa L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. HP (haptoglobin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2152-2153.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HRH1 (histamine receptor H1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2153-2155.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HRH2 (histamine receptor H2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2155.
  • Corzo L, Fernández-Novoa L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. HSD17B1 (hydroxysteroid (17-beta) dehydrogenase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2155-2156.
  • Lombardi V, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HSPA1L (heat shock 70kDa protein 1-like). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2156-2157.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR1A (5-hydroxytryptamine (serotonin) receptor 1A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2157-2159.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR1B (5-hydroxytryptamine (serotonin) receptor 1B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2159-2161.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR1D (5-hydroxytryptamine (serotonin) receptor 1D). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2161.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR2A (5-hydroxytryptamine (serotonin) receptor 2A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2161-2164.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR2C (5-hydroxytryptamine (serotonin) receptor 2C). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2164-2165.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR3A (5-hydroxytryptamine (serotonin) receptor 3A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2165-2168.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR3B (5-hydroxytryptamine (serotonin) receptor 3B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2168-2169.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR3C (5-hydroxytryptamine (serotonin) receptor 3, family member C). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2169.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTR6 (5-hydroxytryptamine (serotonin) receptor 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2169-2170.
  • Carril JC, Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. HTT (huntingtin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2170-2174.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ICAM1 (intercellular adhesion molecule 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2175-2178.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IFNA1 (interferon, alpha 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2178-2179.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IFNB1 (interferon, beta 1, fibroblast). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2179-2181.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IFNG (interferon, gamma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2181-2186.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IGF1 (insulin-like growth factor 1 (somatomedin C)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2186-2189.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IGF2 (insulin-like growth factor 2 (somatomedin A)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2189-2190.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL1B (interleukin 1, beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2190-2196.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL1RN (interleukin 1 receptor antagonist). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2196-2198.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL2 (interleukin 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2198-2201.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL4 (interleukin 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2201-2204.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL6 (Interleukin 6 (interferon, beta 2)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2204-2210.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL6R (interleukin 6 receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2210-2211.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL8RA (interleukin 8 receptor, alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2211-2212.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL8RB (interleukin 8 receptor, beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2212-2213.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL10 (interleukin 10). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2213-2218.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL12B (interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2218-2221.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IL17RB (interleukin 17 receptor B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2221-2222.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. IMPDH1 (IMP (inosine monophosphate) dehydrogenase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2222-2223.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. INPP1 (inositol polyphosphate-1-phosphatase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2223.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. IRF1 (interferon regulatory factor 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2223-2224.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ITGA2 (integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2224-2225.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. ITGB3 (integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2225-2227.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. ITPA (inosine triphosphatase (nucleoside triphosphate pyrophosphatase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2227.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNE1 (potassium voltage-gated channel, Isk-related family, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2228-2229.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNE2 (potassium voltage-gated channel, Isk-related family, member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2229-2230.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNH2 (potassium voltage-gated channel, subfamily H (eag-related), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2230-2232.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNJ11 (potassium inwardly-rectifying channel, subfamily J, member 11). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2232-2234.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KCNQ1 (potassium voltage-gated channel, KQT-like subfamily, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2234-2236.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. KDR (kinase insert domain receptor (a type III receptor tyrosine kinase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2236-2237.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2237-2238.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2239-2241.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. LCK (lymphocyte-specific protein tyrosine kinase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2242.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. LCT (lactase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2243.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LDLR (low density lipoprotein receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2243-2246.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LEP (leptin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2246-2248.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LEPR (leptin receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2248-2249.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LIPC (lipase, hepatic). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2249-2250.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LOXL1 (lysyl oxidase-like 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2250-2251.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LPL (lipoprotein lipase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2251-2253.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LRRK2 (leucine-rich repeat kinase 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2253-2254.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LTA (lymphotoxin alpha (TNF superfamily, member 1)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2254-2256.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LTA4H (leukotriene A4 hydrolase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2256.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. LTC4S (leukotriene C4 synthase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2256-2257.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MAOA (monoamine oxidase A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2258-2259.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MAOB (monoamine oxidase B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2260-2261.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. MAPK7 (mitogen-activated protein kinase 7). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2261.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MAPT (microtubule-associated protein tau). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2261-2266.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. MC1R (melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2266-2267.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MEN1 (multiple endocrine neoplasia I). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2267-2269.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MET (met proto-oncogene (hepatocyte growth factor receptor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2269-2270.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. MGMT (O-6-methylguanine-DNA methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2270-2272.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2272-2274.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MMP2 (matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2274-2276.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MMP3 (matrix metalloproteinase 3 (stromelysin 1, progelatinase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2276-2278.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2278-2279.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-ATP6 (mitochondrially encoded ATP synthase 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2279-2280.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-COI (mitochondrially encoded cytochrome c oxidase I). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2280-2281.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-ND1 (mitochondrially encoded NADH dehydrogenase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2281-2282.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-ND4 (mitochondrially encoded NADH dehydrogenase 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2282-2283.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-ND6 (mitochondrially encoded NADH dehydrogenase 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2283.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-RNR1 (mitochondrially encoded 12S RNA). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2283-2284.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-TK (mitochondrially encoded tRNA lysine). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2284-2285.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MT-TL1 (mitochondrially encoded tRNA leucine 1 (UUA/G)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2285.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTHFR (5,10-methylenetetrahydrofolate reductase (NADPH)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2285-2288.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTNR1A (melatonin receptor 1A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2288-2289.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTNR1B (melatonin receptor 1B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2289-2290.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTR (5-methyltetrahydrofolate-homocysteine methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2290-2291.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. MTTP (microsomal triglyceride transfer protein). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2291-2292.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NAT2 (N-acetyltransferase 2 (arylamine N-acetyltransferase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2293-2296.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NDUFB4 (NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2296.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NEU2 (sialidase 2 (cytosolic sialidase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2296.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NNMT (nicotinamide N-methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2296-2298.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NOS3 (nitric oxide synthase 3 (endothelial cell)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2298-2301.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NOTCH3 (notch 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2301-2302.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NOX1 (NADPH oxidase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2302-2303.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NPC1 (Niemann-Pick disease, type C1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2303-2304.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NPPA (natriuretic peptide precursor A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2304-2305.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NPY (neuropeptide Y). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2305-2306.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NQO1 (NAD(P)H dehydrogenase, quinone 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2306-2309.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. NR1I2 (nuclear receptor subfamily 1, group I, member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2309-2313.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NR1I3 (nuclear receptor subfamily 1, group I, member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2313-2314.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NR3C1 (nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2314-2318.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NRXN1 (neurexin 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2318.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. NTRK2 (neurotrophic tyrosine kinase, receptor, type 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2318-2320.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. OASL (2′-5′-oligoadenylate synthetase-like). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2321.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. OPRM1 (opioid receptor, mu 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2321-2323.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. ORM1 (orosomucoid 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2323.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. P2RY1 (purinergic receptor P2Y, G-protein coupled, 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2324.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. P2RY12 (purinergic receptor P2Y, G-protein coupled, 12). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2324-2325.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PARK2 (parkinson protein 2, E3 ubiquitin protein ligase (parkin)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2325-2326.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PDE1C (phosphodiesterase 1C, calmodulin-dependent 70kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2327.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PDE5A (phosphodiesterase 5A, cGMP-specific). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2327-2328.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PDGFRA (platelet-derived growth factor receptor, alpha polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2328-2330.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PDGFRB (platelet-derived growth factor receptor, beta polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2330-2331.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PEMT (phosphatidylethanolamine N-methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2331-2332.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2332-2333.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. POLG (polymerase (DNA directed), gamma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2333-2335.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PON1 (paraoxonase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2335-2338.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PPARA (peroxisome proliferator-activated receptor alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2338-2340.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PPARD (peroxisome proliferator-activated receptor delta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2340-2342.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PPARG (peroxisome proliferator-activated receptor gamma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2342-2345.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PPARGC1A (peroxisome proliferator-activated receptor gamma, coactivator 1 alpha). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2345-2347.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. PRDX4 (peroxiredoxin 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2347.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PRNP (prion protein). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2347-2352.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PROC (protein C (inactivator of coagulation factors Va and VIIIa)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2352-2353.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PSEN1 (presenilin 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2353-2357.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PSEN2 (presenilin 2 (Alzheimer disease 4)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2357-2359.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGER1 (prostaglandin E receptor 1 (subtype EP1), 42kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2359.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGER2 (prostaglandin E receptor 2 (subtype EP2), 53kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2359-2360.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGER3 (prostaglandin E receptor 3 (subtype EP3)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2360-2361.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGER4 (prostaglandin E receptor 4 (subtype EP4)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2361-2362.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGES (prostaglandin E synthase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2362-2363.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGFR (prostaglandin F receptor (FP)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2363.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGIR (prostaglandin I2 (prostacyclin) receptor (IP)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2363-2364.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGIS (prostaglandin I2 (prostacyclin) synthase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2364-2365.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGS1 (prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2365-2367.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. PTGS2 (prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2367-2373.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. RB1 (retinoblastoma 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2374-2377.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. REN (renin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2377.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. RET (ret proto-oncogene). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2377-2379.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. RGS2 (regulator of G-protein signaling 2, 24kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2379-2380.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. RGS4 (regulator of G-protein signalling 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2380-2381.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. RRAS2 (related RAS viral (r-ras) oncogene homolog 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2381-2382.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. RRM1 (ribonucleotide reductase M1 polypeptide). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2382.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. RYR1 (ryanodine receptor 1 (skeletal)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2382-2383.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCARB1 (scavenger receptor class B, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2384-2385.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN1A (sodium channel, voltage-gated, type I, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2385-2386.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN1B (sodium channel, voltage-gated, type I, beta). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2386.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN2A (sodium channel, voltage-gated, type II, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2386-2387.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN3A (sodium channel, voltage-gated, type III, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2387.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN4A (sodium channel, voltage-gated, type IV, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2387-2388.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN5A (sodium channel, voltage-gated, type V, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2388-2390.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCN9A (sodium channel, voltage-gated, type IX, alpha subunit). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2390-2391.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SCNN1G (sodium channel, nonvoltage-gated 1, gamma). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2391-2392.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC5A5 (solute carrier family 5 (sodium iodide symporter), member 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2392-2393.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC5A8 (solute carrier family 5 (iodide transporter), member 8). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2393-2394.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC6A2 (solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2394-2395.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC6A3 (solute carrier family 6 (neurotransmitter transporter, dopamine), member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2395-2397.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC6A4 (solute carrier family 6 (neurotransmitter transporter, serotonin), member 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2397-2399.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC10A1 (solute carrier family 10 (sodium/bile acid cotransporter family), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2399-2400.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC10A2 (solute carrier family 10 (sodium/bile acid cotransporter family), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2400-2401.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC11A1 (solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2401-2402.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC12A3 (solute carrier family 12 (sodium/chloride transporters), member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2402.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC14A2 (solute carrier family 14 (urea transporter), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2402-3.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC15A1 (solute carrier family 15 (oligopeptide transporter), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2403-2404.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC15A2 (solute carrier family 15 (H+/peptide transporter), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2404.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC19A1 (solute carrier family 19 (folate transporter), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2404-2405.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A1 (solute carrier family 22 (organic cation transporter), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2406.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A2 (solute carrier family 22 (organic cation transporter), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2406-2407.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A4 (solute carrier family 22 (organic cation/ergothioneine transporter), member 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2407-2408.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A6 (solute carrier family 22 (organic anion transporter), member 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2408-2409.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A7 (solute carrier family 22 (organic anion transporter), member 7). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2409-2410.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A8 (solute carrier family 22 (organic anion transporter), member 8). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2410-2411.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC22A16 (solute carrier family 22 (organic cation/carnitine transporter), member 16). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2411-2412.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC23A2 (solute carrier family 23 (nucleobase transporters), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2412.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC28A1 (solute carrier family 28 (sodium-coupled nucleoside transporter), member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2412-2413.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLC28A2 (solute carrier family 28 (sodium-coupled nucleoside transporter), member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2413.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO1A2 (solute carrier organic anion transporter family, member 1A2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2413-2414.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO1B1 (solute carrier organic anion transporter family, member 1B1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2414-2416.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO1B3 (solute carrier organic anion transporter family, member 1B3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2416.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO1C1 (solute carrier organic anion transporter family, member 1C1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2416-2417.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SLCO2B1 (solute carrier organic anion transporter family, member 2B1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2417-2418.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SNAP25 (synaptosomal-associated protein, 25kDa). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2418.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SNCA (synuclein, alpha (non A4 component of amyloid precursor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2418-2420.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SOD2 (superoxide dismutase 2, mitochondrial). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2420-2424.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SOD3 (superoxide dismutase 3, extracellular). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2424-2425.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SPG7 (spastic paraplegia 7 (pure and complicated autosomal recessive)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2425.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SRD5A2 (steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2425-2427.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SSTR2 (somatostatin receptor 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2427.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. SSTR5 (somatostatin receptor 5). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2427-2428.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. STAT3 (signal transducer and activator of transcription 3 (acute-phase response factor)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2428-2431.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1A1 (sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2431-2432.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1A2 (sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2432-2433.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1A3 (sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2433-2435.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1C2 (sulfotransferase family, cytosolic, 1C, member 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2435.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. SULT1E1 (sulfotransferase family 1E, estrogen-preferring, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2435-2436.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TACR2 (tachykinin receptor 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2437.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TAP1 (transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2437-2438.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TBX21 (T-box 21). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2438-2439.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TBXA2R (thromboxane A2 receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2439-2440.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TBXAS1 (thromboxane A synthase 1(platelet)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2440.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TERT (telomerase reverse transcriptase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2440-2442.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TGFB1 (transforming growth factor, beta 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2442-2448.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TGFBR1 (transforming growth factor, beta receptor 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2448-2449.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. THBD (thrombomodulin). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2449-2450.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TIMP3 (TIMP metallopeptidase inhibitor 3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2450-2451.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TLR4 (toll-like receptor 4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2451-2453.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TNF (tumor necrosis factor (TNF superfamily, member 2)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2453-2464.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TNFRSF1A (tumor necrosis factor receptor superfamily, member 1A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2464-2465.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TNFRSF1B (tumor necrosis factor receptor subfamily, member 1B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2465-2467.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TOP1 (topoisomerase (DNA) I). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2467-2468.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TP53 (tumor protein p53). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2468-2474.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TPH1 (tryptophan hydroxylase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2474-2475.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. TPH2 (tryptophan hydroxylase 2). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2475-2476.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TPMT (thiopurine S-methyltransferase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2477.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TPRV1 (transient receptor potential cation channel, subfamily V, member 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2478-2479.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. TYMS (thymidylate synthetase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2479-2481.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UCP2 (uncoupling protein 2 (mitochondrial, proton carrier)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2482-2483.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2483-2490.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A3 (UDP glucuronosyltransferase 1 family, polypeptide A3). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2490-2493.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A4 (UDP glucuronosyltransferase 1 family, polypeptide A4). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2493-2495.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A6 (UDP glucuronosyltransferase 1 family, polypeptide A6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2495-2497.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A7 (UDP glucuronosyltransferase 1 family, polypeptide A7). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2497-2500.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A9 (UDP glucuronosyltransferase 1 family, polypeptide A9). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2500-2502.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT1A10 (UDP glucuronosyltransferase 1 family, polypeptide A10). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2502-2506.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT2B7 (UDP glucuronosyltransferase 2 family, polypeptide B7). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2506-2509.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. UGT2B15 (UDP glucuronosyltransferase 2 family, polypeptide B15). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2509-2510.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. USF2 (upstream transcription factor 2, c-fos interacting). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2510-2511.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. USP5 (ubiquitin specific peptidase 5 (isopeptidase T)). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2511.
  • Lombardi V, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VCAM1 (vascular cell adhesion molecule 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2512-2513.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VDR (vitamin D (1,25- dihydroxyvitamin D3) receptor). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2513-2516.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VEGFA (vascular endothelial growth factor A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2516-2520.
  • Fernández-Novoa L, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VGF (VGF nerve growth factor inducible). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2520.
  • Carril JC, Carrera I, Corzo L, Bello A, Fraile C, McKay A, Cacabelos R. VKORC1 (vitamin K epoxide reductase complex, subunit 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2520-2521.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. WNK1 (WNK lysine deficient protein kinase 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2522-2523.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. WNT5B (Wingless-type MMTV integration site family, member 5B). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2523.
  • Tellado I, Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. XDH (xanthyne deydrogenase). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2524-2525.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. XPA (xeroderma pigmentosum, complementation group A). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2525-2526.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. XRCC1 (X-ray repair complementing defective repair in Chinese hamster cells 1). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2526-2528.
  • Corzo L, Carrera I, Bello A, Fraile C, McKay A, Cacabelos R. ZFAND6 (zinc finger, AN1-type, domain 6). In: Cacabelos R (Ed). World guide for drug use and pharmacogenomics. EuroEspes Publishing, Coruña, 2012:2529.
  • Hanin, I., Cacabelos, R., Fisher, A. Recent Progress in Alzheimer’s and Parkinson’s Diseases. Taylor & Francis, London (2005).
  • Cacabelos, R. (Ed.). Molecular Genetics of Alzheimer’s Disease and Aging. Genomic Medicine Series. Methods and Findings in Experimental and Clinical Pharmacology, Prous Science, Barcelona (2005).
  • Cacabelos, R. Farmacogenómica y Nutracéutica. Progreso Científico y Desarrollo Farmacéutico. Fundación Ebiotec, La Coruña (2004).
  • Takeda, M., Tanaka, T., Cacabelos, R. (Eds.). Molecular Neurobiology of Alzheimer’s Disease. Karger, Basel (2004).
  • Hanin, I., Fisher, A., Cacabelos, R. (Eds.). New Trends in Alzheimer- and Parkinson-Related Disorders. Monduzzi Editore, Bologna, 2003.
  • Cacabelos, R. The histamine-citokine network in Alzheimer disease: Etiopathogenic and pharmacogenomic implications. En: Mapping the Progress of Alzheimer’s and Parkinson’s Disease. Mizuno, Y., Fisher, A., Hanin, I. (Eds.). Advances in Behavioral Biology, 51:59-64 (2002).
  • Cacabelos, R. Prevención de Riesgo Cerebral en Altos Ejecutivos. En: Emprendedores con Valores. El directivo ante el nuevo encuentro Europa-América. Confederación Española de Directivos y Ejecutivos-CEDE (2002).
  • Cano Gutiérrez, C.A., Cacabelos, R., Gómez Restrepo, C., Jacquier, M., Lopera, F., Manssur Calderón, R.A., Mantallana Eslava, D.L., Montañés Ríos, P., Román, G., Téllez Vargas, J.E. Consenso Colombiano de Enfermedad de Alzheimer. Noosfera Ed., Santa Fe de Bogotá, 2001.
  • Cacabelos, R. Enfermedad de Alzheimer. Perspectivas de futuro. En: Libro Blanco sobre la Enfermedad de Alzheimer y Trastornos Afines. R. Fernández-Ballesteros, J. Díez Nicolás (Eds.). Obra Social Caja Madrid, Editorial Médica Panamericana, Madrid, pp. 449-522 (2001).
  • Cacabelos, R. Bases biológicas del envejecimiento cerebral. En: Gerontología Social. R. Fernández-Ballesteros, Pirámide Ed., Madrid, pp. 105-151 (2000).
  • Cacabelos, R., Fernández, C.I., Giacobini, E., Takeda, M. (Eds.). Annals of Psychiatry. Basic and Clinical Neurosciences. Brain Aging and Alzheimer’s disease. Prous Science, Barcelona, Vol. 7 (1999).
  • Cacabelos, R. Tratado de Neurogeriatría. Enfermedad de Alzheimer y Otras Demencias. Epidemiología y Genética. Masson, Barcelona (1999).
  • Cacabelos, R., Winblad, B., Eikelenboom, P. (Eds.). Neurogerontology and Neurogeriatrics. Inflammation and neuroimmunotrophic activity in Alzheimer’s disease. Prous Science, Barcelona, Vol. 2 (1998).
  • Cacabelos, R. Bases moleculares del envejecimiento cerebral. En: Temas de Gerontología II. Universidad de Granada/Ministerio de Trabajo y Asuntos Sociales, pp. 29-41 (1997).
  • Cacabelos, R. Japón. Lecciones de una cultura en salud pública y bienestar social. Prous Science. Barcelona, 1996.
  • Cacabelos, R. Enfermedad de Alzheimer: Factores etiopatogénicos y evaluación genética. Programa de Formación permanente. Federación Farmacéutica, Valencia, Año II, Tomo 10:1-40.
  • Cacabelos, R. (Ed.). Annals of Psychiatry. Basic and Clinical Neurosciences. Vol. 6. Prous Science, Barcelona (1996).
  • Cacabelos, R. Claridad mental y autonomía de comportamiento. Aprender a envejecer sano y activo. IMSERSO. Instituto de Ciencias del Hombre. Madrid, pp. 27-29 (1996).
  • Cacabelos, R., Caamaño, J., Gómez, M.J., Fernández-Novoa, L., Franco-Maside, A., Álvarez, X.A. Therapeutic effects of CDP-choline in Alzheimer’s disease: Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. In: The Neurobiology of Alzheimer’s Disease. Crowdon, J.H., Nitsch R.M., Corkin S., Wurtman R.J. (Eds.). Proc. Eighth Meeting International Study Group on the Pharmacology of Memory Disorders Associated with Aging. Zurich, pp. 471-475 (1995).
  • Cacabelos, R., Takeda, M. (Eds.) Annals of Psychiatry Vol. 5. Basic and Clinical Neurosciences. Prous Science Publishers, Barcelona, 1995.
  • Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). Neurogerontology and Neurogeriatrics Vol. 1. Prous Science Publishers, Barcelona, 1995.
  • Cacabelos, R. IRIS Ed. Newsletters 4:1 (1995).
  • Cacabelos, R. Demencia senil. Enfermedad de Alzheimer. Estrategias terapéuticas. Grupo ASAC (1995).
  • Cacabelos, R. Enfermedad de Alzheimer. Etiopatogenia y tratamiento actual. Proc. V Congreso Comunidad Valenciana Médicos Rurales y Generalistas. Para una mejor Sanidad en la Comunidad. Soc. Española de Medicina Rural y Generalista. SEMERGEN, pp. 69-74 (1995).
  • Gómez, M.J., Caamaño, J., Vinagre, D., Cacabelos, R. Evaluación neuropsicológica de la demencia senil. 7º Curso de Geriatría “Ciudad de San Sebastián”. Fundación Matia, pp. 65-91 (1995).
  • Caamaño, J., Vinagre, D., Gómez, M.J., Franco, A., Cacabelos, R. Demencia: Diagnóstico diferencial. 7º Curso de Geriatría “Ciudad de San Sebastián”. Fundación Matia, pp. 92-119 (1995).
  • Cacabelos, R. Enfermedad de Alzheimer. 7º Curso de Geriatría “Ciudad de San Sebastián”. Fundación Matia, pp. 153-171 (1995).
  • Cacabelos, R. (Ed.). EuroEspes Research Reports 1990-1995. Vol. l. EuroEspes Foundation, La Coruña, 1995.
  • Cacabelos, R. Enfermedad de Alzheimer: Experiencia Clínica con Citicolina. Baliarda, Buenos Aires, 1995.
  • Cacabelos, R. Demencia senil. Enciclopedia Iberoamericana de Psiquiatría. Macropedia. Vol II:359-381 (1995).
  • Cacabelos, R., Takeda, M. (Eds.). Annals of Psychiatry. Basic and Clinical Neurosciences. Prous Science, Barcelona, Vol. 5 (1995).
  • Cacabelos, R. Enfermedad de Alzheimer. Bases etiopatogénicas para nuevas estrategias terapéuticas. En: Neuroinmunoprotección en la demencia senil. Estrategias terapéuticas pleiotrópicas en la enfermedad de Alzheimer. Grupo ASAC. Alicante, pp. 9-39 (1994).
  • Cacabelos, R., Winblad, B. (Eds.). Alzheimer’s Disease. Annals of Psychiatry Vol. 4, Basic and Clinical Neurosciences. Prous Science Publishers, Barcelona, 1994.
  • Cacabelos, R. Diagnosis of Alzheimer’s disease. Definition of AD phenotype/genotype. The Karolinska Institute Postgraduate Education Series. Alzheimer’s disease: Advances in Research and Clinical Practice. Winblad, B., Nordberg, A. (Eds.). pp. 42-45 (1994).
  • Cacabelos, R. New strategies for Alzheimer’s disease treatment: Pleiotropic drugs and multifactorial intervention. In: Alzheimer Disease: Therapeutic Strategies. E. Giacobini, R. Becker. (Eds.). Birkhauser, Boston, pp. 493-498 (1994).
  • Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. Educational pathways for neurogerontology and psychogeriatrics. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 7-9 (1993).
  • Cacabelos, R. Neurobiology of aging. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 33-38 (1993).
  • Gómez, M.J., Cacabelos, R. Neuropsychological markers in psychogeriatrics. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T. Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 67-69 (1993).
  • Franco-Maside, A., Cacabelos, R. Brain mapping in psychogeriatrics. In: I lnternational Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.) EuroEspes Foundation, La Coruña, pp. 71-76 (l993).
  • Caamaño, J., Cacabelos, R. Transcranial Doppler sonography in psychogeriatrics. En: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 77-82 (1993).
  • Álvarez, X.A., Cacabelos, R. Effects of S-9977-2 on learning, behavior, and serum and brain interleukin-1 levels in rats. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 203- 206 (1993).
  • Álvarez, X.A., Franco, A., Fernández-Novoa, L., Cacabelos, R. Effects of Anapsos on behavior and brain cytokines in rats. En: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 211-214 (1993).
  • Álvarez, X.A., Franco, A., Fernández-Novoa, L., Caamaño, J., Novo, B., Gómez, M.J., Zas, R., Rettori, M.C., Kamoun, A., Polo, E., García, M., Cacabelos, R. Effects of S-9977-2 on behavior and brain interleukin-1. En: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 219 (1993).
  • Álvarez, X.A., Franco, A., Fernández-Novoa, L., Zas, R., Novo, B., Cacabelos, R. Effects of anapsos on behavior and brain cytokines. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 220 (1993).
  • Álvarez, X.A., Franco, A., Fernández-Novoa, L., Caamaño, J., Novo, B., Gómez, M.J., Zas, R., Cacabelos, R. Age-dependent variations in serum interleukin-1 and tumor necrosis factor alpha levels in humans. En: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 221 (1993).
  • Caamaño, J., Franco, A., Gómez, M.J., Novo, B., Álvarez, X.A., Fernández-Novoa, L., Cacabelos, R. Acute effects of CDP-Choline on middle cerebral artery blood flow velocities in Alzheimer’s disease: A transcranial Doppler study. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 222 (1993).
  • Caamaño, J., Franco, A., Gómez, M.J., Novo, B., Álvarez, X.A., Fernández-Novoa, L., Cacabelos, R. Cerebrovascular effects of CDP-choline in patients with Alzheimer’s disease: A transcranial Doppler study. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 223 (1993).
  • Franco-Maside, A., Caamaño, J., Gómez, M.J., Álvarez, X.A., Fernández-Novoa, L., Novo, H., Cacabelos, R. CDP-Choline-induced brain mapping changes in patients with Alzheimer’s disease. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 224 (1993).
  • Franco-Maside, A., Caamaño, J., Cacabelos, R. Brain electrical activity mapping correlates with cerebral blood flow velocity in Alzheimer’s disease. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 225 (1993).
  • Gómez, M.J., Cacabelos, R. Relationship between word recall and location in a ten-word list of the Alzheimer’s Disease Assessment Scale. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 227 (1993).
  • Gómez, M.J., Álvarez, X.A., Cacabelos, R. Dementia mood assessment scale in elderly controls and in patients with depression and/or cognitive impairment. In: I International Course on Neurogerontology and Psychogeriatrics. Cacabelos, R., Frey, H., Nishimura, T., Winblad, B. (Eds.). EuroEspes Foundation, La Coruña, pp. 228 (1993).
  • Cacabelos, R., Álvarez, X.A., Franco-Maside, A., Fernández-Novoa, L., Caamaño, J. Influence of CDP-choline on cognition and interleukin-1 in Alzheimer’s disease and multi-infarct dementia. In: Alzheimer’s disease and related disorders. Nicolini, M., Zatta, P.F., Corain, B. (Eds.). Advances in Biosciences. Vol. 87. Pergamon Press, London, pp. 347-348 (1993).
  • Cacabelos, R. Etiopatogenia de la enfermedad de Alzheimer. En: Demencia: Un nuevo reto para la asistencia de ancianos. J.C. Caballero García, Ed. Barcelona, pp. 43-57 (1993).
  • Cacabelos, R., Franco-Maside, A., Álvarez, X.A. Influence of the somatotropinergic system on mental function and psychomotor activity: Environmental factors, development, cognition, and neuropsychiatric disorders. In: Human Growth: Basic and Clinical Aspects. Hernández, M., Argente, J. (Eds.). Elsevier, Amsterdam, pp. 161-172 (1992).
  • Cacabelos, R. Brain histamine: Psychoneuroimmune regulator in physiological and pathological conditions. In: Proc. 1st Int. Congr. Vitamins and Biofactors in Life Sciences. Kobayashi, T., Ed. Center For Academic Publications, Japan, pp. 573-576 (1992).
  • Cacabelos, R. Neurobiología molecular de la enfermedad de Alzheimer: Prospecciones terapéuticas. En: Actas I Simposio de Psicobiología. Pásaro, E. Ed. Serv. Public. Univ. Coruña, pp. 27-51 (1992).
  • Cacabelos, R. (Ed.). Basic and Clinical Neurosciences. Annals of Psychiatry, Vol. 3 (1992).
  • Cacabelos, R. Neurobiología del GRF: Aspectos básicos y aplicaciones clínicas. En: Péptidos reguladores gastrointestinales. Blázquez, E., Tamarit, J. (Eds.). Fundación Areces, Madrid, pp. 185-204 (1992).
  • Cacabelos, R. Histaminergic regulation of the neuroendocrine system. En: Histaminergic Neurons: Morphology and Functions. Ch.14. Watanabe, T., Wada, H. (Eds.). CRC, Florida, pp. 241-270 (1991).
  • Cacabelos, R., Rubia, F.J. Perspectivas neurobiológicas en hiperquinesia infantil. En: Neurotransmisión y plasticidad sináptica. Esquerda, J.E., Gallego, R., Gual, A., Ramírez, G., Rubia, F. Spaxs, Barcelona, pp. 261-291 (1991).
  • Cacabelos, R., Franco-Maside, A., Álvarez, X.A. Neurobiología de la histamina cerebral. En: Biopatología de los sistemas histaminérgicos cerebrales. Varela de Seijas, E. Duphar Pharmaceutica Ed., Madrid, pp. 11-48 (1991).
  • Rubia, F.J., Martín-Loeches, M., Gil, P., Expósito, F.J., Miguel, F., Cacabelos, R. Mapas de actividad eléctrica cerebral en la demencia senil de tipo Alzheimer y en la demencia cerebrovascular durante tareas cognoscitivas. En: Bases neuroquímicas del envejecimiento cerebral: enfermedad de Alzheimer. Peinado Herreros, J.M., Iribar Ibabe, M.C. (Eds.). Univ. Granada, pp. 113-131 (1991).
  • Martín-Loeches, M., Gil, P., Miguel, F., Expósito, F.J., Cacabelos, R., Rubia, F.J. Potenciales evocados tardíos en la enfermedad de Alzheimer. En: Bases neuroquímicas del envejecimiento cerebral: enfermedad de Alzheimer. Peinado Herreros, J.M., Iribar lbabe, M.C. (Eds.). Univ. Granada, pp. 133-148 (1991).
  • Cacabelos, R., Rubia, F.J. Alteraciones neuroquímicas en la enfermedad de Alzheimer. En: Bases neuroquimicas del envejecimiento cerebral: enfermedad de Alzheimer. Peinado Herreros, J.M., Iribar Ibabe, M.C. (Eds.). Univ. Granada, pp. 289-312 (1991).
  • Cacabelos, R. Nuevas estrategias terapéuticas en la enfermedad de Alzheimer: psicofarmacología molecular de los agentes nootropos y potencial utilidad de los factores neurotróficos. En; Proc. II Reun. Nac. Soc. Esp. Gerontopsiquiat. Psicogeriat., Bobes García, J., Arán Ed., Madrid, pp. 57-78 (1991).
  • Cacabelos, R. Avances en la enfermedad de Alzheimer. En: Gerontología 1992. Jiménez Herrero, F. (Ed.). CEA Ed., Madrid, pp. 69-82 (1991).
  • Cacabelos, R. (Ed.). Enfermedad de Alzheimer: Etiopatogenia, neurobiología y genética molecular, diagnóstico y terapéutica. J.R. Prous Eds., S.A., Barcelona, 1991.
  • Cacabelos, R., Álvarez, X.A. Función neuroinmune en trastornos mentales. Actas XV Reun. Soc. Esp. Psiq. Biol., Córdoba, 1-3.XI.91. ELA, Madrid, 1:7-14 (1991).
  • Cacabelos, R. (Ed.). Anuario Psiquiátrico. Vol. 2. J.R. Prous Eds., S.A., Barcelona (1991).

Divulgación y opinión

  • Cacabelos R. Pharmacogenomics of polypharmacy in Alzheimer’s disease. http://www.adjacentopenaccess.org/nhs-health-social-care-news/pharmacogenomics-polypharmacy-alzheimers-disease/34264/
  • Cacabelos R. Misuse of pharmacotherapy: Danger on the horizon. http://www.adjacentgovernment.co.uk/category/nhs-health-social-care-news/.
  • Cacabelos R. Epigenetics: The missing link at the frontier of health and disease. http://www.adjacentgovernment.co.uk/category/nhs-health-social-care-news/.
  • Cacabelos R. Pharmacogenomics in neuropsychiatric disorders. http://www.adjacentgovernment.co.uk/category/nhs-health-social-care-news/.
  • Cacabelos R. The silent progression of Parkinson’s disease. http://www.adjacentgovernment.co.uk/category/nhs-health-social-care-news/.
  • Cacabelos R. El mundo de Jonathan Livingston Harguindey. El Correo Gallego, 4 Enero, pp. 6, 2015.
  • Cacabelos R. The challenges of Pharmacogenomics and Personalized medicine in an aged population. Adjacent Government 7. http://edition.pagesuite-professional.co.uk. Page 368. 2015. http://www.adjacentgovernment.co.uk/category/nhs-health-social-care-news/.
  • Cacabelos R. Genomic Medicine: the reconceptualization of Health and Disease. http://www.adjacentgovernment.co.uk/category/nhs-health-social-care-news/.http://www.adjacentgovernment.co.uk/category/ebooks/
  • Cacabelos R. Drug development for Alzheimer’s disease. http://www.adjacentgovernment.co.uk/category/nhs-health-social-care-news/.http://edition.pagesuite-professional.co.uk/launch.aspx?eid=793abb3f-e692-439f-9236-554269c9e570
  • Cacabelos R. Alzhéimer: prevención contra el riesgo y tratamiento personalizado contra el daño. El Faro de Vigo, 18 Septiembre, pp. 17, 2015.
  • Cacabelos R. Cuando perdemos la memoria. El Correo Gallego, 20 Septiembre, pp. 7, 2015
  • Cacabelos R. El martillo del Herrero. El Correo Gallego, 27 Septiembre, pp. 7, 2015.
  • Cacabelos R. Soluciones al gasto por enfermedad. http://diario.eleconomista.es/1/578734-eleconomista-sanidad-01-octubre-2015.
  • Cacabelos R. El papel es nuestra vida. El Correo Gallego, 11 Octubre, pp. 6, 2015.
  • Cacabelos R. Égloga a mi presidente (I). El Correo Gallego, 22 Octubre, pp. 16, 2015.
  • Cacabelos R. Égloga a mi presidente (II). El Correo Gallego, 23 Octubre, pp. 18, 2015.
  • Cacabelos R. Medicina genómica de los trastornos mentales. La nueva revolución conceptual en psiquiatría. http://www.psiquiatria.com/psiq_general_y_otras_areas/genetica/medicina-genomica-de-los-trastornos-mentales-la-nueva-revolucion-conceptual-en-psiquiatria/
  • Cacabelos R. Investigación Biomédica y Medicina Personalizada. La Cultura del Conocimiento. El Correo Gallego. Especial Medicina. 16 Dic. Pp. 3-5 (2015).
  • Cacabelos R. Desvaríos en el lupanar político. Gen-T 2015; 10:3.
  • Cacabelos R. Al profesor universitario. Gen-T 2015; 10:199-200.
  • Cacabelos R. Priorizar las inversiones y una buena gestión serán clave para salir de la crisis. El Correo Gallego. 31 Diciembre,pp. 28-29, 2014.
  • Cacabelos, R. La biblia de la genómica. Gen-T 9:3-5 (2013).
  • Cacabelos, R. Ética de progreso en tiempo de crisis. Alterius non sit qui sus ese potest. Gen-T 9:177-178 (2013).
  • Cacabelos, R. Pepinos, parásitos e intoxicaciones. Gen-T 7:3 (2011).
  • Cacabelos, R. Consejos a un Presidente. Gen-T 7:96-98 (2011).
  • Cacabelos, R. El Alzheimer comienza 30 años antes de manifestarse. El Correo Gallego. http://www.elcorreogallego.es/popImprimir.php?idWeb=1&idNoticia=702652.
  • Cacabelos, R. Historias de la aldea, un poco de paz navideña (… y feliz traspaso de incompetencias). Gen-T 8:3 (2011).
  • Terrón, F., Kiener, P.A., Ortiz, P., Cacabelos, R., Hug, P. Biotecnología. En: Ponencias VI Congreso de Directivos CEDE. Liderando en positivo. Pamplona, 29-30 Oct. Sodena. Sociedad de Desarrollo de Navara, pp. 279-312 (2010).
  • Cacabelos, R. La crisis de la salud social. Gen-T 5:3 (2010).
  • Cacabelos, R. Consejos a un hijo (adolescente). Gen-T 5:97-98 (2010).
  • Cacabelos, R. Reforma sanitaria. Gen-T 6:3 (2010).
  • Cacabelos, R. Consejos a un colega (médico). Gen-T 6:97-98 (2010).
  • Cacabelos, R. Paso a la cultura del conocimiento. Gen-T/The EuroEspes Journal, 4:3 (2009).
  • Cacabelos, R. Los retos de la medicina genómica y el paradigma de la farmacogenética. Rev. Esp. Economía Salud, 7:5-6 (2008).
  • Cacabelos, R. Medicina personalizada versus medicina numeralizada. Gen-T/The EuroEspes Journal, 3:3 (2008).
  • Cacabelos, R. Los genios de la locura. Evolución del conocimiento sobre la enfermedad mental. Gen-T/The EuroEspes Journal, 3:28-45 (2008).
  • De la Torre, J., Cacabelos, R. Patología cardio-cerebrovascular en la enfermedad de Alzheimer. Gen-T/The EuroEspes Journal, 3:56-65 (2008).
  • Harguindey, S., Orive, G., Anitua, E., Arranz, J.L., Cacabelos, R., Díaz de Otazu, R., Meléndez Hevia, E. Hacia un enfoque integrado de las enfermedades neurodegenerativas. Gen-T/The EuroEspes Journal, 3:82-89 (2008).
  • Cacabelos, R. The abyssal waters of personalized medicine. Gen-T/The EuroEspes Journal, International Edition, 2:5-7 (2008).
  • Cacabelos, R. Specula orbis. Gen-T/The EuroEspes Journal, 1:3 (2007).
  • Cacabelos, R. Medicina genómica y enfermedad de Alzheimer. Gen-T/The EuroEspes Journal, 1:30-38 (2007).
  • Cacabelos, R. Stultia mentis. Gen-T/The EuroEspes Journal, 2:3 (2007).
  • Cacabelos, R. Genética del dolor de cabeza. El enigma de la herencia en las migrañas. Gen-T/The EuroEspes Journal, 2:32-44 (2007).
  • Cacabelos, R. La genética familiar es el primer factor de riesgo para padecer Alzheimer. Acofar, 469: 16-18 (2007).
  • Cacabelos, R. La Unión Europea se abraza a la Farmacogenómica. El Global, 10-16 Sept. (2007).
  • Cacabelos, R. La Medicina Genómica del Futuro. Boletín das Ciencias, 62:67-69 (2006).
  • Cacabelos, R. El Legado de Garkok. Fundación Ebiotec, La Coruña (2006).
  • Cacabelos, R. Función cerebrovascular en la enfermedad de Alzheimer. Sinapsis. www.sinapsis.org (2006).
  • Cacabelos, R. Exposición Fotográfica: Por la Galicia Natural. Fundación Ebiotec y Ayuntamiento de A Coruña (2006).
  • Freeman, G., Cacabelos, R. Pensamientos de outsider. Fundación Ebiotec, La Coruña (2005).
  • Cacabelos, R. Educación y Fugas…de Cerebros. ECO 140:70 (2003).
  • Cacabelos, R. Enfermedad de Alzheimer. Retos para el futuro. Júbilo 47:24-27 (2003).
  • Cacabelos, R. Progreso biotecnológico en España. Ejecutivos 134: 46-47 (2003).
  • Cacabelos, R. Salud mental y prevención de riesgo cerebral en altos ejecutivos. ECO 130:71 (2002).
  • Cacabelos, R. Plan de prevención genética de la enfermedad de Alzheimer. ECO 131:50 (2002).
  • Cacabelos, R. Progreso biotecnológico. ECO 132:60 (2002).
  • Cacabelos, R. Impacto del Genoma Humano en la Economía Mundial. ECO 133:50 (2002).
  • Cacabelos, R. Economía y Salud. ECO 135:44 (2002).
  • Cacabelos, R. Saber o no saber: Esa es la diferencia. ECO 136:44 (2002).
  • Cacabelos, R. Criterios de Excelencia. ECO 137:78 (2002).
  • Cacabelos, R. Pensando en Japón. ECO 138:52 (2002).
  • Cacabelos, R. Salvemos el mar. ECO 139:52 (2002).
  • Cacabelos, R. Enfermedad de Alzheimer. Retos para el futuro. Alzheimer en Asturias. Nº 2, Julio-Diciembre (2002).
  • Cacabelos, R. Patología vascular y demencia: asociación de alto riesgo. Consejos de tu Farmacéutico 35:16-17 (2002).
  • Cacabelos, R. Genética de los trastornos mentales. Consejos de tu Farmacéutico 36:20-21 (2002).
  • Cacabelos, R. La geografía del prión. El Cultural, 7/2:56-57 (2001).
  • Cacabelos, R. Medicina Predictiva y Genoma. ByN Dominical II/57:70 (2001).
  • Protocolo diagnóstico y terapéutico de pacientes de proyecto ADI. I Curso de Orientadores y IV de Profesores ADI. Centro Médico EuroEspes, Bergondo, La Coruña. (23.2.2000).
  • Bases biológicas de la vejez. Envejecimiento normal. Máster de Gerontología Social. Especialidad en Calidad de Servicios Gerontológico. Facultad de Psicología. Universidad Autónoma de Madrid. (17.3.2000).
  • Neurobiología del envejecimiento humano patológico. Máster de Gerontología Social. Especialidad en Calidad de Servicios Gerontológico. Facultad de Psicología. Universidad Autónoma de Madrid. (17.3.2000).
  • Salud Mental y Bienestar Personal. Bases biológicas de los procesos neurodegenerativos. Vacaciones Inteligentes 2000. Lanzarote. (21-23.7.2000).
  • Malatia d’Alzheimer: Etioaptogènia, genética i farmacogenòmica. Conferencia de Cloenda. Hospital Universitari del Mar, Sessions Clíniques, Barcelona. (25.5.2000).
  • Investigación básica y clínica en la enfermedad de Alzheimer. Cursos de Verano de Extensión Universitaria. Universidad de Oviedo. Avances en la enfermedad de Alzheimer. Cátedra Jovellanos de Extensión Universitaria, Gijón. (4.7.2000).
  • Trastornos neuropsiquiátricos en la enfermedad de Alzheimer. Cursos de Verano de Extensión Universitaria. Universidad de Oviedo. Avances en la enfermedad de Alzheimer. Cátedra Jovellanos de Extensión Universitaria, Gijón. (4.7.2000).
  • Muerte cerebral y eutanasia. Universidad de Verano SEK. ¿Hay vida después de la vida? La respuesta de la ciencia y el pensamiento de vanguardia. Universidad SEK, Segovia. (3-5.7.2000).
  • Enfermedad de Alzheimer. Causas y futuro terapéutico. Universidad Islas Baleares. Palma de Mallorca. (15.9.2000).
  • Programa de intervención en demencias. Universidad Islas Baleares, Palma de Mallorca. (16.9.2000).
  • Estrategias terapéuticas en la enfermedad de Alzheimer. Hacia un tratamiento integral. Hotel Bogotá Royal, Bogotá, Colombia. (28.6.2000).
  • Cacabelos, R. Educación, madurez cerebral y prevención del fracaso escolar. Programa ADI, CIBE, La Coruña (2000).
  • Cacabelos, R. Operación Genoma. Europa pagará un alto precio por quedarse atrás. Muy Interesante 229:28 (2000).
  • Cacabelos, R. Prólogo a “Manual de cuidados básicos de una enfermedad familiar (Enfermedad de Alzheimer)”. Autor: Miguel Muñoz-Cruzado y Barba. Drug Farma, Madrid, 1998.
  • Cacabelos, R. Enfermedad de Alzheimer. Reto y compromiso. DKV Previasa Magazine. 2:13-17 (1998).
  • Adeva Candenas, J., Flórez-Lozano, J.A., Caballero-García, J.C., Cacabelos, R., García García, M.C., Martínez Lage, J.M., Maújo Iglesias, B.A. Las demencias en el presente y en el futuro. JANO LII/1203:929/33 (1997).
  • Cacabelos, R. Demencia senil: El reto del siglo XXI. JANO LII/1203:930-936/34-40 (1997).
  • Cacabelos, R. Un juicio a la bioingeniería. ABC de la Ciencia. 279:55 (1997).
  • Cacabelos, R. El Alzheimer, prioridad sociosanitaria para el siglo XXI. El Diario Montañés, pp. 4 (9.5.1997).
  • Cacabelos, R. Cerebro y conciencia. Recensiones bibliográficas. Med. Clín., 109:288 (1997).
  • Cacabelos, R. Premio a la perseverancia innovadora. La Vanguardia, pp. 27 (7.10.1997).
  • Cacabelos, R. Enfermedad de Alzheimer: Muerte celular y riesgo genético. Diario Médico, 20 Sept., pp. 15 (1996).
  • Cacabelos, R. El reto de la enfermedad de Alzheimer. ABC Cultural. ABC de la Ciencia. (27.9.1996), 256:62 (1996).
  • Cacabelos, R. Prólogo a “Enfermedad de Alzheimer. Aspectos psicosociales”. Autor: J.A. Flórez Lozano. EDIKAMed, Barcelona, 1996.
  • Cacabelos, R. Alzheimer: Aspectos médicos y sociofamiliares. Punto de Encuentro, 9:20-23 (1995).
  • Cacabelos, R. Avances en el tratamiento del mal de Alzheimer. ABC Cultural de la Ciencia, Madrid, 7 Enero, pp. 56 (1994).
  • Cacabelos, R. Tetrahidroaminoacridina: Una esperanza terapéutica para la enfermedad de Alzheimer. JANO Med. Hum., 1082:57-60 (1994).
  • Cacabelos, R. New functional aspects of the suprachiasmatic nucleus of the hypothalamus. Med. Clin. 102:526,531,539 (1994).
  • Cacabelos, R. Nuevas posibilidades terapéuticas en la enfermedad de Alzheimer. Diario Médico, Junio 6, pp. 12 (1994).
  • Cacabelos, R. Alzheimer: Nuevas esperanzas para una enfermedad temible. ABC Cultural. ABC de la Ciencia. Julio 1, pp. 52-53 (1994).
  • Cacabelos, R. Neurofarmacología molecular de la enfermedad de Alzheimer. Primeras generaciones de fármacos anti-demencia. Dirección Farmacéutica 5:48-54 (1994).
  • Cacabelos, R. El reto de las neurociencias. Anuario Sístole, pp. 78-79 (1993).
  • Cacabelos, R. Sistema de salud japonés: un modelo de rentabilidad y eficacia. JANO Med. Hum., 1048:19-20 (1993).
  • Cacabelos, R. Estrategias científicas ante el siglo XXI. Anuario Sístole. 101 (1992).
  • Cacabelos, R. En Japón hay en la actualidad 14 millones de personas mayores de 65 años. JANO Med. Hum., 977:21 (1992).
  • Cacabelos, R. Demencia-SIDA. JANO Med. Hum., 984:31-44 (1992).
  • Cacabelos, R. Planificación sanitaria. Sístole, 98:4 (1992).
  • Cacabelos, R. Tratamiento actual de la enfermedad de Alzheimer. Sístole, 100:51 (1992).
  • Cacabelos, R. La fase de recesión económica en la que ha entrado Japón podría llegar a originar cambios muy importantes en su política científica. JANO Med. Hum., 996:35 (1992).
  • Cacabelos, R. Futuro de la investigación sobre la enfermedad de Alzheimer. Noticias Médicas, 3468:89-90 (1992).
  • Cacabelos, R. Neurociencias, economía y salud. Sístole, 107:4 (1992).
  • Cacabelos, R. Enfermedad de Alzheimer: El reto de la psicofarmacología molecular. JANO Med. Hum., 1000:161-164 (1992).
  • Cacabelos, R. La inteligencia artificial en Japón tras el fracaso de la quinta generación de ordenadores. JANO Med. Hum., 999:34-36 (1992).
  • Cacabelos, R. Perspectivas de futuro para el Alzheimer. Diario Médico, 14 Julio, 1992.
  • Cacabelos, R. Soluciones a la crisis sanitaria (I). Sístole 120:2 (1992).
  • Cacabelos, R. Soluciones a la crisis sanitaria (II). Sístole l23:2 (1992).
  • Cacabelos, R. Soluciones a la crisis sanitaria (III). Sístole 125:2 (1992).
  • Cacabelos, R. Soluciones a la crisis sanitaria (IV). Sístole 126:2 (1992).
  • Cacabelos, R. Demencia senil: prioridad sanitaria. El Correo Gallego. Medicina. 20.12.92, pp. 5 (1992).
  • Cacabelos, R. La participación industrial en la investigación académica. JANO Med. Hum., 936:26 (1991).
  • Cacabelos, R. Desarrollo de la psicología y de las ciencias cognitivas en Japón. JANO Med. Hum., 939:23-24 (1991).
  • acabelos, R. Las autoridades niponas diseñan estrategias en la lucha antidroga. JANO Med. Hum., 938:24-26 (1991).
  • Cacabelos, R. La medicina tradicional china (Kampo) sigue estando vigente en Japón. JANO Med. Hum., 940:32-33 (1991).
  • Cacabelos, R. Genética de la enfermedad de Alzheimer. JANO Med. Hum., 948:44-64 (1991).
  • Cacabelos, R. Las estrategias de control de calidad en Japón ayudan a abaratar la sanidad, simplificar los esquemas asistenciales y mejorar la salud. JANO Med. Hum., 954:23-24 (1991).
  • Cacabelos, R. Calidad de vida y bienestar: influencia de la medicina japonesa. JANO Med. Hum., 963:27-28 (1991).
  • Cacabelos, R. Gestión científica: un embrión de buenas intenciones. Sístole, 84:9 (1991).
  • Cacabelos, R. Décadas de tradición, evolución y progreso en la medicina japonesa. JANO Med. Hum., 970:28-32 (1991).
  • Cacabelos, R. Una de las preocupaciones de un amplio sector de la sociedad japonesa se centra en buscar salida al sufrimiento de los enfermos terminales. JANO Med. Hum., 972:28-30 (1991).

Déjenos sus datos y nosotros nos pondremos en contacto con usted

Déjenos sus datos y nosotros nos pondremos en contacto con usted